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ABSTRACT 
Ischaemic heart disease and stroke are the most common causes of death in the world, both 
diseases being manifestations of atherosclerotic cardiovascular disease. Atherosclerosis is a 
slow process initialized by the retention and accumulation of cholesterol rich lipoproteins in 
the innermost layer of the artery wall. Activation of an inflammatory response with the 
recruitment of immune cells lead to a buildup of plaques in the vessel. Both innate immune 
cells, most prominently macrophages, and adaptive immune cells play important roles in all 
stages of the development of atherosclerosis. 
Metabolism is intimately linked with atherosclerosis development. Systemically increased 
levels of metabolites such as cholesterol and glucose are known risk factors for atherosclerosis. 
The metabolism in the microenvironment of the atherosclerotic plaque shape the immune 
response and influence disease progression. Immune cell metabolism of glucose and amino 
acids have been suggested as possible targets for future therapy. While modern therapies are 
effective at reducing known risk factors such as hyperlipidemia, considerable risk remains and 
few therapies for atherosclerosis target the underlying inflammatory mechanisms that drive the 
disease. 
In Paper I the effect of indoleamine 2,3-dioxygenase (IDO) mediated tryptophan metabolism 
on atherosclerosis was investigated.  Pharmacological inhibition of IDO with 1-methyl-
tryptophan resulted in increased atherosclerotic burden in mice. Furthermore, in vitro data 
showed that the expression of pro-inflammatory molecules was increased on smooth muscle 
cells upon IDO inhibition. Treatment with the downstream tryptophan metabolite  
3-hydroxyanthranilic acid (3-HAA) reversed both the in vivo and in vitro effects of IDO 
inhibition. 
The effects of 3-HAA on lipoprotein metabolism was studied in Paper II. Activity of the 
transcription factor sterol response element binding protein 2 (SREBP2) was decreased when 
HepG2 hepatoma cells were treated with 3-HAA. Mice treated with the pharmacological 
inhibitor of the 3-HAA degrading enzyme 3-HAA oxygenase had less atherosclerotic plaque 
size and lower plasma lipids. In vitro experiments also showed 3-HAA to be a potent inhibitor 
of the inflammasome in macrophages. 
In Paper III we showed that the metabolism of tryptophan is altered in human atherosclerotic 
disease. Patients with symptoms had an impaired metabolism of tryptophan to kynurenic acid, 
a metabolite that can induce anti-inflammatory responses, possibly via aryl hydrocarbon 
receptor activation. In Paper IV we demonstrate that the small molecule dichloroacetate 
(DCA), a known inhibitor of glycolysis, reduces atherosclerosis lesion size, plasma lipids and 
reprograms the immune system towards an anti-inflammatory phenotype. We also show that 
DCA is a potent inhibitor of inflammasome production of IL-1β. 
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1 IMPACT OF ATHEROSCLEROTIC DISEASE 
During the last century, diseases of the heart and blood vessels, known as cardiovascular 
disease (CVD), have replaced communicable diseases as the main cause of mortality in the 
world. Ischaemic heart disease is the single most common cause of death, accounting for 16.6% 
of total deaths globally in 2016, followed by stroke which caused 10.2% of deaths in the same 
year. The most common cause of death not related to CVD, chronic obstructive pulmonary 
disease, accounted for 5.4% of global mortality. A similar pattern is seen across all income 
levels, except in the countries with lowest income where communicable disease still drives 
mortality rates. While a small decrease in mortality rates can be seen in countries with the 
highest income, CVD deaths globally are on the rise (1).  
Apart from being the principal cause of death and disability, CVD is also the most important 
cause of costs for developed healthcare systems. The total direct and indirect cost of CVD 
(including stroke) in the United States was estimated at an annual average of $329.7 billion for 
2013 to 2014. That accounts for 14% of total health expenditures and is the highest cost of any 
diagnostic group. By 2035, 45.1% of the total population of the United States is predicted to 
suffer from at least one CVD, and total costs for CVD-related illness are predicted to rise to 
$749 billion (2). 
Both of the main causes of death, ischaemic heart disease and stroke, are commonly caused by 
atherosclerosis. Atherosclerosis is recognized by the focal thickening of the inner most layer 
of the artery wall, the intima, a feature known as atheroma or atherosclerotic plaque. These 
atherosclerotic plaques contain lipids, several types of cells, connective tissue and debris. A 
premature form of the atherosclerotic plaque is the fatty streak, an aggregation of lipid-laden 
immune cells in the intima. Fatty streaks are seen in young patients and may recede or may 
develop into atherosclerotic plaques. The atherosclerotic plaques may mature over time and 
cause symptoms, either through the slow growth of a stable plaque obstructing arterial flow, or 
through rupture of the plaque and the sudden formation of an intra-arterial thrombus, the latter 
giving rise to acute onset end-organ ischaemia (3).  
Through epidemiological studies, several risk factors for atherosclerosis have been found. The 
current concept of risk factors for atherosclerosis was first introduced as a result of the 
Framingham Heart Study (4). The risk factors discovered within the Framingham Heart Study 
include tobacco smoking, hypertension, hypercholesterolemia (specifically elevated low-
density lipoprotein cholesterol [LDL-C] and decreased high-density lipoprotein cholesterol 
[HDL-C]), age, male sex and diabetes mellitus (5). Several of these risk factors are highly 
prevalent in the population; for example, 62% of Swedish men and 42% of women are expected 
to suffer from hypertension (6) and in 2015-2016, at least 12.4% of the adult U.S. population 
was estimated to suffer from hypercholesterolaemia (7). However, while conventional risk 
factors account for approximately 75% of CVD, substantial risk remains (8). Furthermore, even 
optimal treatment of risk factors in patients identified to be predisposed for CVD events does 
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not offer adequate protection, and considerable risk remains even with current preventive 
treatment (9). Thus a need for additional approaches in the treatment of CVD is apparent. 
1.1 HUMAN ATHEROSCLEROSIS IS AN INFLAMMATORY DISEASE   
The notion that atherosclerosis is an inflammatory disease was put forward in the 19th century 
by Rudolf Virchow (10), with Nikolai Anitschkow adding important insight into the role of 
cholesterol in vascular inflammation in the early 20th century. An important step in achieving 
acceptance of the hypothesis of inflammation as a main factor in atherosclerosis was taken with 
the discovery of an association between the acute phase reactant C-reactive protein (CRP) and 
atherosclerosis by Attilio Maseri et al. (11). In 1997, it was demonstrated that an elevated serum 
CRP level was associated with an increased risk of a vascular event later in life (12). The 
measurement of CRP is a common procedure to determine the level of inflammation in a 
patient, and the potential clinical applicability of this finding led to a wider spread of the notion 
that inflammation is intimately linked with the onset and progression of atherosclerosis.  
However, the clinical findings of the 1990s were founded on several experimental observations 
relating CVD and atherosclerosis to inflammation made in the previous decade. Several 
inflammatory molecules such as cytokines and growth factors were previously associated with 
atherosclerosis in experimental studies (13). Other epidemiological evidence of the relationship 
between inflammation and atherosclerosis comes from the observation that patients suffering 
from autoimmune disease have an increased risk of CVD. The presence of rheumatoid arthritis, 
one of the most common autoimmune diseases, increases the risk of myocardial infarction by 
a magnitude approximately similar to that of the conventional risk factor diabetes mellitus (14). 
The implication of inflammation and the immune system in the pathogenesis of atherosclerosis 
holds the promise of new therapeutic options targeting the cause of atherosclerosis. In 2017, 
the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) was the first 
randomized controlled trial to successfully show that an intervention directly targeting immune 
function could reduce CVD events and death independently from affecting conventional risk 
factors (15). The interleukin (IL) 1β targeting monoclonal antibody Canakinumab was used in 
patients with a previous myocardial infarction and an elevated level of high-sensitivity CRP 
(hsCRP ≥ 2 mg/l). While a decrease was seen in the primary endpoint (recurrent myocardial 
infarction, stroke or cardiovascular death), treatment with Canakinumab significantly increased 
the risk of mortality due to severe infection. This highlights both the potential of 
immunomodulatory treatment of CVD as well as it demonstrates the need for increased 
knowledge about the immune system and immune mechanisms in atherosclerosis to improve 
future therapies. 
2 THE IMMUNE SYSTEM 
Components of the immune systems are implicated in all stages of atherosclerotic disease. The 
immune system is a collective name for several cell types, tissues and organs dispersed 
throughout an organism tasked with defending the host against infection. To do so, an advanced 
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ability to discriminate between conditions that should give rise to a protective immune 
response, and conditions that should not, is needed so that an immune response is not developed 
against the organism’s self. Apart from foreign microorganisms, the intricate immune system 
of a human must also clear away debris from normal cell turnover, remove mutated cells and 
plays an essential part in maintaining normal homeostasis. These diverse tasks call for 
extensive crosstalk between the immune system and other organ systems, and a great variety 
of available immune responses. 
 
2.1 THE INNATE IMMUNE SYSTEM 
The immune system ccn be divided into the innate immune system and the adaptive immune 
system. The innate immune system is the first line of defence against infection, specialized at 
recognizing invading microorganisms and alerting the slower but more specific adaptive 
immune system. Epithelial barriers, such as skin and mucosa, are part of the innate immune 
system and apart from physically hindering pathogens from entering the host, these organs 
normally secrete antimicrobial molecules. Once in the host, microorganisms are recognized by 
the innate immune system by receptors that bind molecular motifs specific for infectious 
agents. These molecular motifs are often referred to as pathogen-associated molecular patterns 
(PAMPs). Molecules associated with tissue damage also give rise to an innate immune 
response, and these molecules are usually seen as damage-associated molecular patterns 
(DAMPs). The receptors that recognize PAMPs and DAMPs are called pattern recognition 
receptors (PRRs)(16). 
2.1.1 Innate immune receptors 
There are several PRRs. A notable family of PRRs is the Toll-like receptors (TLRs). Located 
on the cell surface are TLRs recognizing components of bacteria. Examples of cell-surface 
TLRs are TLR4 which binds lipopolysaccharide, TLR5 which binds flagellin, TLR2 which 
binds peptidoglycan and, TLR1 and TLR6 that are involved in the recognition of bacterial 
lipopeptides. Endosomal TLRs recognize components of nucleic acids often seen during viral 
infections such as dsRNA (TLR3), ssRNA (TLR7 and TLR8) and CpG DNA (TLR9). Most 
often, TLRs function as homo- or heterodimers. Once activated, TLRs signal through the 
mediator protein MyD88 to activate the transcription factor nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB). Alternatively, some signals are transduced via TIR-
domain-containing adapter-inducing interferon-β (TRIF), leading to the transcription of type 1 
interferons (INF-I) (17, 18).  
Another important family of PRRs is the nucleotide-binding oligomerization domain-like 
receptors (NOD-like receptors; NLRs). In contrast to membrane-bound TLRs, NLRs are 
cytosomal receptors and respond to a wide variety of PAMPs and DAMPs. There are at least 
22 different NLRs that can be subdivided based on the N-terminal domain of the receptor. The 
N-terminal domain is responsible for receptor effector functions and interacts with other 
proteins. There are four main types of NLR N-terminal domains: the acidic transactivation 
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domain (NLRA), the baculoviral inhibitory repeat-like domain (NLRB), the caspase activation 
and recruitment domain (NLRC) and the pyrin domain (NLRP) (19). The C-terminus of the 
receptor is responsible for sensing and recognizing ligands. Several PAMPs and DAMPs are 
recognized by different NLRs, including components of bacteria and viruses; extracellular 
adenosine triphosphate (ATP); changes in intracellular ion concentration; monosodium  
urate-, calcium pyrophosphate- and cholesterol crystals; free fatty acids; and reactive oxygen 
species. Some NLRs, such as NLRC1 (also known as NOD-1) and NLRC2 (also known as 
NOD-2) function in a similar manner as TLRs in that when activated, the receptors stimulate 
transcription of pro-inflammatory genes through the activation of NF-κB (20). Other NLRs 
recruit other cytosolic proteins to form multimeric complexes called inflammasomes. 
One of the most studied inflammasomes is the NLRP3 (also known as NALP3) inflammasome. 
Ligands for NLRP3 are structurally varied and include toxins or whole-pathogen components 
from microorganisms such as Candida albicans and Staphylococcus aureus as well as host-
derived molecules such as extracellular ATP, and monosodium urate- or cholesterol-crystals. 
The activation of the inflammasome is tightly regulated, and during physiological conditions 
counteracting inhibitory mechanisms are believed to block aberrant inflammasome activation. 
The end product of inflammasome activity is the secretion of the mature forms of the cytokines 
IL-1β and IL-18. To achieve this several steps are required, of which the first is priming of the 
inflammasome.  
During priming, pro-inflammatory signals such as TLR ligation and activation, or signals from 
pro-inflammatory cytokines such as tumour necrosis factor (TNF) and subsequent activation 
of NF-κB induce the transcription of components necessary for inflammasome function. 
Mainly the immature pro-form of IL-1β (pro-IL-1β) is needed as most cells do not have a ready 
supply of this cytokine during resting conditions. Additionally, components of the 
inflammasome machinery such as NLRP3 itself are increasingly transcribed upon pro-
inflammatory signalling. Once primed, an activating signal is needed to initiate the assembly 
of the inflammasome proteins. The activation is typically ligation of NLRP3 with one of its 
agonists. Once activated, NLRP3 recruits the adaptor protein “associated speck-like protein 
containing CARD” (ASC). The final component in the complex is pro-caspase-1 and several 
complexes oligomerize to form the mature inflammasome. Pro-caspase-1 is cleaved and thus 
activated, and in turn caspase-1 cleaves pro-IL-1β into mature IL-1β that is secreted. 
Inflammasome activation is a potent pro-inflammatory mechanism and is known to induce 
pyroptosis, a form of cell death. Failed inhibition or overactivation of the inflammasome is 
associated with several autoimmune disorders such as periodic fever syndromes, but has also 
more recently been implicated in chronic diseases such as diabetes mellitus type 2 (21). 
2.1.2 Monocytes and macrophages 
Several cell types make up the innate immune system. The first cells to encounter a pathogen 
or initiate an inflammatory response are often mononuclear phagocytosing cells such as 
monocytes or macrophages. Monocytes derive from CD34+ myeloid progenitor cells in the 
bone marrow. A supply of circulating monocytes is continuously released into the circulation. 
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Upon infection or inflammation, the bone marrow output of monocytes can be quickly 
increased, mainly as a response to cytokines such as granulocyte colony-stimulating factor (G-
CSF), C-C-motif-ligand 2 (CCL2) and CCL5. The spleen also functions as a reservoir for 
monocytes to be recruited after inflammatory stimuli. Traditionally, two populations of 
monocytes have been described in human circulation: the classical monocytes, identified by 
CD14++CD16- and non-classical monocytes, CD14dimCD16+. A similar division into two 
subsets can be made of murine monocytes, where the Ly6C+CCR2+CX3CR1
low cells are short 
lived and quickly recruited in to inflamed tissues while Ly6C-CCR2-CX3CR1
high cells migrate 
into non-inflamed tissues. However, with increasing ability to differentiate monocytes, the 
paradigm of two subsets has been challenged, and an intermediate subset of human monocytes 
has been proposed (CD14+CD16+HLA-DR+CD86+CD11c+). Classical monocytes would then 
gradually differentiate into non-classical monocytes by passing the intermediate stage. The 
function of the classical monocyte is to migrate to inflamed tissues, phagocytose antigens, and 
initiate the immune response. Intermediate monocytes display upregulation of several 
processes related to antigen presentation and are believed to be important for activation of the 
adaptive immune response as well as apoptosis control. Non-classical monocytes are important 
in antibody-mediated phagocytosis and in patrolling blood vessels. The transition between 
classical and non-classical monocytes is not clear-cut and with the advent of more advanced 
tools such as mass spectrometry coupled flow cytometry, an increasing number of further, 
partially overlapping, subdivisions of the monocyte population have been added.  (22, 23) 
Once migrated into an inflamed tissue, monocytes may differentiate into macrophages and 
dendritic cells (DCs); however, not all macrophages are derived from monocytes. A large 
portion of tissue resident macrophage populations are already established in foetal life and are 
not dependent on monocyte infiltration during adult life. Macrophages differentiated from 
monocytes are believed to have specific functions and phenotypes compared with tissue 
resident macrophages; however, the contribution of origin versus the contribution of local 
factors to macrophage function is still debated. Organs with self-renewing tissue resident 
macrophages include the brain, epidermis, lung and liver. The heart and pancreas have a slow 
renewal of their macrophage pool by infiltrating monocytes while the gut and dermis have a 
fast turnover of macrophages with a pronounced infiltration of circulating monocytes (24).  
Another common way to subdivide macrophages other than being tissue resident or not, is 
based on their cytokine and receptor response to stimulation. Macrophages activated by ligation 
of TLRs as a response to invading foreign microorganisms primarily develop into a pro-
inflammatory phenotype called M1 macrophages. Pro-inflammatory cytokines, particularly 
interferon-γ (INF-γ), also polarize macrophages into the M1 phenotype. Functionally, M1 
macrophages specialize in phagocytosing foreign antigens and cell debris, killing and 
degrading phagocytosed material, and maintaining the inflammatory response. Upregulation 
of the transcription of pro-inflammatory cytokines such as TNF and IL-12b is a signature of 
M1 macrophages, as is a change in arginase metabolism with upregulation of inducible nitric 
oxide synthase (iNOS) to generate the free radical nitric oxide (NO). M2 macrophages are on 
the other end of the spectrum compared to pro-inflammatory M1 macrophages, as M2 
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macrophages play important roles in wound healing, resolution of inflammation and 
maintaining tissue homeostasis. Most of tissue resident macrophages are not activated during 
normal conditions and could be argued to be of the M2 phenotype. In vitro, a similar phenotype 
can be achieved by polarizing macrophages with the cytokines IL-4 and IL-13. Typical M2 
macrophages express arginase instead of iNOS. M2 macrophages secrete the pro-tolerogenic 
cytokines IL-10 and transforming growth factor β (TGF-β), which are important in tissue 
repair. Components of the NLRP3 inflammasome also seem to be downregulated in M2 
macrophages.  
The dichotomy of dividing macrophages into M1 and M2 macrophages is, however, a 
simplification. For example, several subsets of M2 macrophages have been described (M2a, 
M2b and M2c), and each subset depends on different stimuli for polarization. Furthermore, 
other subsets of macrophages have been described, such as regulatory macrophages (Mregs), 
macrophages induced by oxidized lipids (Mox) and M4 macrophages. The applicability of the 
M1 and M2 classification, a nomenclature mainly sprung from the stimulation of macrophages 
in vitro, in the in vivo setting is also being questioned. It is clear that macrophages are a highly 
plastic cell type with the ability to change between several functions and roles depending on 
local stimuli and that classification should be done on a continuous spectrum rather than into 
clear-cut populations (25-28). 
2.1.3 Dendritic cells  
Dendritic cells (DCs) have traditionally been described to be of myeloid lineage like 
monocytes. Modern views on haematopoiesis have, however, given nuance to that belief, 
suggesting that myeloid and lymphoid potentials run together longer than previously suggested 
and explaining the observed lymphoid markers in some subsets of DCs. DCs originate in the 
bone marrow and are then released into the circulation. In the human setting, there are three 
main subsets of DCs: conventional DCs 1 and 2 (cDC1 and cDC2 respectively) and 
plasmacytoid DCs (pDCs). Finally, monocytes can differentiate into DCs under certain 
conditions, and are then called monocyte-derived DCs (mo-DC).  
In the activation of the immune response, DCs have two functions. The first is to collect antigen 
and transport it to an appropriate lymphoid organ. To do so, DCs are spread throughout most 
tissues of the body but are particularly abundant at sites commonly exposed to foreign 
microorganisms, such as epithelial barriers. DCs form a cellular net throughout the tissues of 
the body where they sample their environment and take up antigens using a wide array of PRRs. 
Once an antigen is taken up and an inflammatory response is initiated, DCs lose adhesion to 
their environment and start to migrate along a chemokine gradient towards a lymph node (LN).  
The DCs then begin to mature and to perform their second task in initiating an immune 
response, which is to present the antigen to the adaptive immune system and initiate an 
appropriate adaptive response. During the maturation process, the lysosomes of the DCs acidify 
to breakdown and process the antigen into small peptides. The antigen peptides are displayed 
on major histocompatibility complex class II (MHC-II) molecules that are trafficked to the cell 
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surface. To activate a robust immune response, DCs are also producers of cytokines and 
microbial activation induces the production of TNF, IL-12 and other pro-inflammatory 
cytokines. Dendritic cells that have not undergone maturation do not display antigen to the 
same extent. However, displaying the antigen is not enough to initiate an immune response. An 
additional signal is needed such as co-stimulation of the adaptive immune system by the DC, 
e. g., by CD80 or CD86. During resting conditions, DCs seem to play an important role in 
maintaining tolerance towards self-antigens while presenting endogenous peptides without co-
stimulation.  
The cDC2 subset seems to have the broadest ability to present foreign antigens and give rise to 
a wide variety of adaptive immune responses, even tolerogenic ones. In the case of cDC1, this 
subset is specialized in promoting a cellular immune response aimed at activating CD8+ T cells 
and a T-helper cell type 1 (TH1) response. pDCs are named for their morphological similarity 
with plasma cells, and the function of pDCs is particularly important in combatting viruses and 
neoplasia. TLR7 and TLR9, both receptors of nucleic acid elements are abundant in pDCs and 
upon activation, pDCs produce large quantities of INF-I. In certain autoimmune diseases and 
experimental settings, pDCs have been found to be tolerogenic and to induce regulatory cells 
of the adaptive immune response (29-31). 
2.1.4 Granulocytes 
Granulocytes, sometimes referred to as polymorphonuclear cells due to the multilobulated 
shape of their nuclei, are the most abundant immune cells in human blood. The most numerous 
granulocytes are neutrophils, numbering between approximately 1.6 and 5.9 million cells per 
milliliter of blood in healthy adults, constituting 50% to 70% of circulating immune cells (in 
mice, however, neutrophils constitute approximately 10% to 25% of circulating white cells) 
(32). At times of inflammation such as infection, the count of neutrophils quickly increases 
under the influence of G-CSF, sometimes doubling the count. Neutrophils are generated in the 
bone marrow. Once formed, they patrol the circulation, and during physiological conditions, 
they have limited survival in tissues. Exceptions are sites of reservoirs of mature neutrophils, 
such as the spleen and lungs, where mature neutrophils carry out surveillance and function as 
a pool to quickly recruit cells from in the event of inflammation. During inflammation the 
lifespan of neutrophils is substantially prolonged.  
Neutrophils are the first responders at sites of inflammation. Local cells of the innate immune 
system are activated, secreting pro-inflammatory cytokines that activate the endothelium. By 
binding to selectins and subsequently to integrins, neutrophils first roll along and then attach to 
the activated endothelium. Once attached, the neutrophil moves across the endothelium and out 
into the inflamed tissue. Several effector functions are available to mature neutrophils. The 
neutrophils are adept phagocytes and can quickly phagocytose bacteria or sterile antigens. 
Additionally, as the name granulocyte implies, neutrophils are loaded with granules that can 
be released upon activation. The granules are filled with cytotoxic components such as 
myeloperoxidase or proteolytic enzymes. Finally, neutrophils may expel their DNA to form 
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net-like structures called neutrophil extracellular traps (NETs) coated with enzymes to trap and 
kill invading microorganisms (33). 
Based on staining properties, two other forms of granulocytes exist, eosinophils and basophils. 
Eosinophils play an important role in defending the host against helminth and parasitic 
infection but are also implied in late phase hypersensitivity reactions. Basophils are rare white 
blood cells that also play a role in hypersensitivity reactions. 
2.1.5 Additional innate immune cells 
Mast cells are bone marrow derived innate immune cells. Typical mast cells have a strong 
affinity for immunoglobulin E (IgE) antibodies mainly through the FcεRI receptor. This 
affinity for IgE makes mast cells important effector cells in type 1 hypersensitivity reactions. 
Upon stimulation, mast cells release preformed granulae containing histamine, tryptase and 
chymase. Mast cells have been found in atherosclerotic plaques and have been argued to 
influence macrophage cholesterol uptake (34). In addition to mast cells, the innate immune 
system also includes natural killer cells (NK-cells) that are important in the defence against 
tumours and intracellular pathogens. Recently, innate cells from the lymphoid lineage called 
innate lymphoid cells (ILCs) have been discovered. 
2.1.6 Complement 
The innate immune system comprises a humoral arm made up of acute phase proteins and the 
complement system. The complement system is made up of several proteolytic proteins 
forming an enzymatic cascade, allowing for great amplification of the response upon 
activation. Three different pathways activate the complement system. The classical pathway is 
dependent on antibody coating of a pathogen to initiate the first signal. Certain molecular 
structures on microbes may directly activate the so called alternative pathway of complement 
activation. Third, mannose-binding lectin may also activate the complement cascade. 
Regardless of the mode of activation, the pathways join in the cleavage of complement factor 
C5 which initiates the assembly of a protein structure called the membrane attack complex 
(MAC). The MAC may then form a pore in the membrane of the microbe, killing it. However, 
the coating of microbes with complement, targeting them for phagocytosis by macrophages or 
neutrophils, is probably of greater functional importance than the direct bactericidal functions 
of the complement system. To not coat cells belonging to the self, an array of inhibitory 
molecules present at most cell membranes inhibit the binding of complement (35). 
2.2 THE ADAPTIVE IMMUNE SYSTEM 
While the innate immune system is tasked with detecting foreign microorganisms and alerting 
the organism of danger and infection, it falls on the adaptive immune system to mount an 
effective response. Furthermore, the adaptive immune system is capable of immunologic 
memory, which improves the response should the same antigen be encountered again. If the 
innate immune system is rigged for detecting common and repeating patterns found in 
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pathogens, the adaptive immune system excels at diversity. The main cells of the adaptive 
immune system are two types of lymphocytes, T cells and B cells. 
2.2.1 T cells  
While originating in the bone marrow, immature T cells migrate to the thymus to undergo 
maturation. The purpose of maturation is to generate T cells that are active enough to respond 
to pathological antigens but not activated when encountering host antigens. At the heart of this 
process is an antigen recognizing surface receptor called the T-cell receptor (TCR). The most 
common TCRs are heterodimers made up of one α chain and one β chain (36). The chains 
contain both constant domains (C) and variable domains (V) where the V-domains are 
responsible for antigen recognition.  
The complete repertoire of antigens recognized by the pool of T cells is at least 2.5 × 107 but 
potentially as large as over 1020 antigens (37), and to achieve such diversity, genes encoded in 
the germline would not suffice. Instead, T cells have developed an advanced system to 
introduce variability in the peptide sequence of the antigen-sensing domain of the TCR. First, 
several variants of gene segments for the antigen-sensing domain exist that can be assembled 
in different combinations by lymphocyte-specific recombinases (recombination activating 
gene; RAG 1 and 2) to generate large variety. Second, in the recombination step, several 
changes to the nucleotide sequence are added, making the variation in the resulting sequence 
increase dramatically. This process does however allow for the generation of non-functioning 
sequences or even sequences that are not able to be translated into protein. Selection is therefore 
needed. In a process referred to as positive selection, only clones of T cells with intact TCRs 
that are able to bind antigen presenting receptors (MHC-II) are given stimuli for further 
maturation, and clones without functioning TCRs undergo apoptosis. Negative selection occurs 
when the maturing T cells that react strongly to self-antigens are removed. Conventional T cells 
can only detect peptide antigens presented by an antigen-presenting cell (APC) on an MHC-II 
molecule. The distribution of a specific TCR is clone specific, meaning that each T cell clone 
has a unique TCR that reacts to a specific antigen. 
To become fully activated, T cells require two signals. The first signal (signal 1) is ligation of 
the TCR by an antigen displayed on MHC-II by an APC. A typical second signal (signal 2) is 
provided by costimulatory molecules on the APC, the most well-known of which are B7-1 
(CD80) and B7-2 (CD86). Costimulatory molecules are upregulated on APCs by 
microorganisms or pro-inflammatory cytokines, thus ensuring that signal 2 is only present 
during an inflamed state. CD80 or CD86 binds to CD28 on T cells, which mediates the second 
signal to T cells. Another set of molecules important for co-stimulation of T cells are CD40 on 
APCs and CD40 ligand (CD40L) on activated T cells. Instead of functioning as co-stimulation 
per se, ligation of CD40 on APCs upregulates regular co-stimulatory molecules on the APC, 
thus allowing the activated T cell to aid in initiating an immune response. Other molecular 
interactions inhibit the immune response; for example cytotoxic T-lymphocyte-associated 
protein 4 (CTLA-4) and programmed cell-death protein 1 (PD-1) bind ligands on APCs but 
inhibit the immune response. 
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T cells that have not yet been activated are referred to as naïve T cells. Once activated, most 
often by APCs that have migrated to a secondary lymphoid organ, the T cell starts to proliferate. 
As the specificity of the TCR is clonal, the number of T cells that recognize a particular antigen 
is greatly expanded. Of this expanded pool of antigen-specific T cells, most are recruited to 
carry out immune effector functions and are thus called effector cells, and when the stimulus 
of the particular antigen is cleared, these cells undergo apoptosis. A small fraction of cells, 
however, turn in to more long-lived memory cells, increasing immune response efficiency 
against future challenge by the same antigen.  
2.2.2 T-cell types 
Two types of conventional T cells exist, CD4+ T cells and CD8+ T cells. CD8+ cells are often 
referred to as cytotoxic T-lymphocytes (CTLs) as they are mediators of cellular immunity. To 
be activated, CTLs are stimulated by antigens bound to major histocompatibility complex class 
I (MHC-I) molecules. MHC-I displays intracellular antigens from the cytosol and is present on 
all cells, while specialized APCs such as DCs may display phagocytosed antigens on MHC-I 
as well. This affinity for MHC-I makes CTLs important for immunity against intracellular 
pathogens such as viruses and intracellular bacteria. Once an activated CTL binds its 
corresponding antigen presented on MHC-I, it may secrete granule proteins such as granzymes 
and perforins that mediate cell death. An alternative effector function is to ligate the Fas 
receptor of an infected cell, causing apoptosis. 
CD4+ T cells have effector functions that enhance or fine tune other arms of the immune 
system, mainly by secreting cytokines or providing stimulatory cell-to-cell interactions, and 
are therefore referred to as T-helper (TH) cells. There are several subsets of TH cells based on 
the profile of their secreted cytokines and effector functions, where each TH cell subset typically 
is dominant in a particular type of immune response (38). TH cells that are activated in the 
presence of INF-γ and IL-12 activate the transcription factor T-box-containing protein 
expressed in T cells (T-bet) and become TH1 cells. TH1 cells are important for protection against 
intracellular bacteria and are adept at inducing bactericidal activity in phagocytosing cells of 
the innate immune system.  
INF-γ is the most important cytokine secreted by TH1 cells, not only activating macrophages 
and polarizing them towards M1, but also maintaining the TH1 response as a positive feedback 
loop. If IL-4 instead is present during TH cell activation, a TH2 response is initiated. The main 
transcription factor governing TH2 polarization is GATA-binding protein 3 (GATA-3). TH2 
cells are part of the immune response to parasites such as helminths and secrete IL-4 and IL-5, 
which potentiate eosinophil function. In addition, TH2 cells secrete IL-10, which downregulates 
TH1 responses and together with other TH2 cytokines, promotes M2 macrophage polarization. 
A particular subset of TH cells are TH17 cells, named after their hallmark secreted cytokine, IL-
17. TH17 cells develop by the actions of pro-inflammatory cytokines such as IL-23, IL-6 and 
IL-1 as well as to some degree TGF-β. The main transcription factor driving the TH17 response 
is RAR-related orphan receptor gamma isoform t (RORγt), and TH17 cells are important in 
fighting extracellular bacteria (36, 39). 
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Regulatory TH cells (TReg) are important in maintaining immune tolerance against the self and 
for regulating pro-inflammatory immune responses. TReg cells comprise approximately 5-7% 
of CD4+ T cells and are classically recognized as CD4+CD25+ cells with upregulation of the 
transcription factor forkhead box P3 (FOXP3). TReg cells can be generated already in the 
thymus or alternatively develop in the periphery as inducible TReg cells (iTReg), mainly in 
conjunction with gut epithelial barriers, under the influence of TGF-β. While thymic TReg cells 
display TCRs mainly recognizing self-antigens, iTReg cells have TCRs specific for a broad 
variety of substances, including innocuous foreign antigens. TReg cells maintain immunological 
tolerance during homeostasis and downregulate the immune response against their cognate 
antigen. To do this, TReg cells secrete regulating cytokines, such as IL-10 and TGF- β, as well 
as display regulatory molecules such as CTLA-4 (40). 
Finally, a specific subset of T cells, called natural killer T cells (NKT-cells), may be generated 
in the thymus. NKT cells display a unique set of TCRs that recognize a variety of lipid antigens. 
The TCRs of NKT cells display less variety than regular T cells, and specific lipid components 
of bacteria activate several clones of NKT cells. Lipid antigens are presented to NKT cells on 
the CD1d molecule, expressed not only on APCs but also on several other tissue cells. Although 
often more sensitive to activation than conventional T cells, NKT cells require APC stimulation 
to fully activate, for example via CD80/CD86 ligation, and are sensitive to co-inhibitory 
pathways such as PD-1 ligation. Upon activation, NKT cells produce cytokines similar to a 
TH1 response (41).   
2.2.3 B cells 
The other major lymphocyte population is, similarly as T cells, originated in the bone marrow 
from lymphoid progenitor cells. However, instead of migrating to the thymus for maturation, 
this lymphocyte population matures in the bone marrow and is thus referred to as B cells. B 
cells are responsible for the humoral arm of the adaptive immune system by differentiating into 
antibody-producing plasma cells. Similar to T cells, each B-cell clone has a unique affinity for 
a particular antigen. However, B cells do not have TCRs; instead they recognize antigens by 
membrane-bound antibodies, sometimes referred to as B-cell receptors (BCRs). 
Antibodies, also known as immunoglobulins (Ig), contain four peptide chains, two heavy 
chains with a light chain each, connected by disulfide bonds to form a Y-shaped tetramer. The 
heavy chain contains 3 or 4 constant regions (C) and one variable region (V), whereas the light 
chain contains only one C and one V region. Variability in the V region is achieved through 
the action of recombinase analogous to the generation of the TCR. The V regions of one heavy 
and one light chain align to give each Ig two antigen binding sites. While the conventional TCR 
only recognizes peptide antigens displayed by MHC-II molecules, the tertiary structure of the 
antigen binding region of Ig allows binding of other types of antigens, as well as antigens not 
displayed by MHC molecules. There are two types of light chains, κ and λ, and each B cell is 
restricted to one type. Five types of heavy chains exist, α, γ, δ, ε, and μ, and Ig are classified by 
their heavy chain into IgA, IgG, IgD, IgE, or IgM respectively. BCRs are of IgD or IgM class, 
IgA is associated with mucosal immunity, IgE is implicated in parasite defence and eosinophil 
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activation as well as hypersensitivity, while IgG is the main class of a fully developed humoral 
adaptive immune response (36). 
Specific signals are required to activate B cells. Several BCRs usually need to be ligated at 
once to activate a naïve B cell. Once activated, B cells may initiate the production of IgM and 
become short-lived plasma cells. To develop a more potent humoral response, T-cell 
interactions are necessary. The stimulated B cell endocytoses the bound antigen and may start 
to migrate towards the T-cell zone in a secondary lymphoid organ. B cells function as 
competent APCs for the antigen recognized by their respective BCR. In the borders between 
the follicle and T-cell zones, the B cell displaying peptide antigens of the endocytosed antigen 
may encounter a TH cell with specificity for the displayed antigen. The TH cell may then activate 
the B cell, for example, by CD40-CD40L interaction or by secreted cytokines. Activated B 
cells may then migrate to the follicle and proliferate rapidly, forming a germinal centre.  
Through the interaction with specific follicular T-helper cells (TFH), the type of heavy chain 
expressed by the B cell may change from μ to form other classes of Ig (e.g., IgG or IgE) in a 
process called class switching. In the DNA coding for Ig V regions, there is a highly increased 
rate of mutation during the germinal centre reaction. Through interaction with specialized 
follicular dendritic cells supplying pro-survival signals conditioned by antigen binding, B-cell 
clones producing Ig with the highest affinity are selected in a process called affinity maturation. 
Many of the high-affinity Ig expressing B cells develop into long-lasting plasma cells that 
produce large quantities of Ig. Some B cells however, develop into memory B cells that patrol 
tissues and the circulation for a long time, allowing for an efficient response upon challenge by 
the same antigen again (36, 42). 
The largest population of B cells are the follicular B cells responsible for the above-described 
germinal centre formation. Another population, marginal zone B cells, is also found in 
secondary lymphoid organs. Both follicular B cells and marginal zone B cells come from the 
B-2 cell population. A third population of B cells, B-1 cells, is mainly found around mucosal 
interfaces, primarily in the gut and peritoneal cavity but also in the pleura. The B-1 cell 
population is believed to be foetal in origin and maintained by self-renewal. One of the major 
functions of B-1 cells is to secrete natural antibodies, mainly of the IgM or IgG3 type. Targets 
of natural antibodies are pathogen-associated structures such as cell wall components of 
bacteria, but B-1 cells seem to be specific for self-antigens to a larger extent than are other B 
cells, and natural antibodies also recognize antigens such as lipid molecules, which could be of 
particular interest in atherosclerosis. A recently discovered B-cell subset is BReg cells, which 
are induced by TLR9 stimulation and similarly to TReg cells have tolerogenic functions, for 
example, via the production of IL-10 and TGF-β (43, 44). 
2.3 TOLERANCE AND RESOLUTION OF INFLAMMATION 
Much research efforts has been made to map the intricate machinery that initiates an immune 
response against a foreign antigen. This is expected, as defending the host against foreign 
pathogens is arguably the main function for which the immune system evolved. Paul Ehrlich 
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observed however, by the beginning of the 20th century, the devastating effects of when this 
system fails and the immune system is turned on the self in what Ehrlich called horror 
autotoxicus (45). During resting conditions, the immune system is not activated. From the 
earlier view of this merely being an absence of antigen, this state of tolerance is now determined 
to depend on several active functions. Furthermore, as inflammation is a central part of the 
pathophysiology in many modern diseases, the need for suppression of the inflammatory 
response is ever increasing. With chronic inflammatory diseases on the rise, interest in how the 
inflammatory response is resolved has seen a tremendous increase. 
2.3.1 Tolerance  
Immune tolerance is the absence of immune reactions to the self and the state in which the 
immune system is during homeostasis. Mechanisms of tolerance are sometimes divided into 
peripheral tolerance and central tolerance, where central tolerance is the process of negative 
selection in the generation of lymphocytes and peripheral tolerance is the generation of 
tolerance-maintaining cells in the tissues (such as iTReg cells). TReg cells are important effector 
cells for maintaining tolerance (36). Important T-cell dependent mechanisms of tolerance are 
the ligation of CTLA-4 and PD-1. Ligation of these co-inhibitory molecules to their receptors 
blocks T cell proliferation, induces anergy, downregulates the production of pro-inflammatory 
cytokines and promotes the production of tolerogenic cytokines such as IL-10 and TGF-β. 
Tolerogenic signals can, however, already be provided by the innate immune system. Local 
factors in the microenvironment may push DCs to develop into tolerogenic DCs, often with a 
pDC-like morphology. Instead of activating naïve T cells, tolerogenic DCs cause T-cell anergy 
and secrete anti-inflammatory cytokines such as IL-10. The role of DCs in activating the 
adaptive immune system for a particular antigen makes tolerogenic DCs particularly interesting 
in autoimmune disease, given their ability to induce tolerance against a specific antigen (46, 
47). Other innate cells important for immune tolerance are M2 macrophages that inhibit pro-
inflammatory M1 responses. A less homogenous population of tolerance-induced innate cells 
are myeloid-derived suppressor cells (MDSCs). The MDSCs are not of clear lineage but 
comprise immature myeloid cells with features of both monocytes, DCs and granulocytes. 
During inflammation, particularly chronic inflammation, the population of MDSCs is 
increased, a focus of interest in tumour escape research (48). 
Local tolerogenic conditions vary between tissues and anatomical sites. It has long been known 
that sites where an inflammatory reaction would have particularly negative consequences have 
strong mechanisms that inhibit local inflammatory reactions. These sites are said to be immune 
privileged, and examples include the central nervous system (CNS), the eye, the gravid uterus, 
testes, hair follicles, liver and the gut. From originally being seen as mostly an anatomical 
feature of barriers inhibiting the circulation of immune cells, such as the blood-brain barrier in 
the CNS and the unique circulation of the eye, immune privilege is now viewed as an active 
process that depends on local regulatory cells and the production of regulatory cytokines and 
cell ligands in the tissue. It has been proposed that the tunica media of arteries is a tissue with 
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increased immune privilege and that breakdown of this immune privilege is central in many 
CVDs (49, 50). 
While mechanisms of tolerance are active processes that can be downregulated upon challenge 
with PAMPs or DAMPs, most pharmacological modulation of the immune system relies on 
immune suppression. The suppressive effects of anti-inflammatory and immunosuppressive 
agents remain the same regardless of the challenging antigen (e.g., an IL-1 targeting antibody 
will deplete IL-1 regardless of the physiological state of the organism or activation of the 
immune system). The unspecific nature of such treatments makes them prone to cause 
unwanted effects such as susceptibility to infection. The modulation of host tolerance and 
resolution pathways presents an attractive alternative approach for future treatment options 
(51). 
2.3.2 Resolution of inflammation 
Immune reactions and the inflammatory process are not only aimed at clearing pathogens. An 
integral part of the inflammatory response is tissue repair and a return to homeostasis, and every 
inflammatory reaction can be divided into an initiation phase and a resolution phase. While the 
predominant view for a long time was that with the removal of the causative antigen, the 
inflammatory response automatically diminished through the passive diffusion and dilution of 
pro-inflammatory mediators, it is now clear that resolution is an active process with a distinct 
cell and molecular machinery.  
The process of resolution begins early in the inflammatory response, even before the causative 
antigen is removed (52). One hallmark feature of resolution is the clearance of dead cells, 
apoptotic bodies and other debris by macrophages. During the resolution process, macrophages 
are polarized to a more M2-like phenotype specialized at efferocytosing apoptotic bodies and 
debris. Signals promoting resolution include not only common tolerogenic mediators such as 
IL-10 and the effect of TReg cells but also specialized pro-resolving mediators (SPMs). SPMs 
are lipid mediators such as lipoxins, resolvins, maresins and protectins, which are derived from 
the ω-3 fatty acids eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), 
docosapentaenoic acid (DPA) and the ω-6 fatty acid arachidonic acid. Signalling pathways for 
the SPMs include specialized G-protein coupled receptors (GPR), mainly ALX/FPR2 and 
ChemR23. Apart from the SPMs, the protein annexin A1 is an important mediator of resolution, 
as are the gaseous mediators NO and H2S (53). 
3 METABOLISM 
The reactions between molecules within an organism to generate energy or building blocks for 
new material constitute its metabolism. Metabolic processes are tightly regulated and variations 
in metabolism give important signals to the cell regarding both the extracellular and the 
intracellular environment. An ability to adapt metabolism to the needs of the current conditions 
is necessary for survival. While specific metabolic pathways exist for important classes of 
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nutrients such as lipids, amino acids and glucose, a tight linkage and overlap between metabolic 
pathways is common. 
3.1 LIPID METABOLISM 
Lipids are essential for all cells and tissues; as the main part of cell membranes, to store and 
distribute energy, for physical insulation and as part of signalling molecules. A particular class 
of lipids are sterols, most notably cholesterol. Lipids are acquired through the digestion of 
ingested nutrients and de novo synthesis.  
3.1.1 Lipoprotein metabolism 
The mean dietary intake of fat of the modern day population is between 30% and 40% of total 
energy intake, which is close to the nutritional recommendation for the Nordic countries of fat 
constituting 25 – 40% of total energy intake (54, 55). The majority of the ingested fat 
(approximately 95%) is esterified into triacylglycerols (TAGs). TAGs are hydrolysed by 
lipases in the gastrointestinal tract to free fatty acids (FFAs) and monoacylglycerols (MAGs) 
and, together with phospholipids and components of bile, emulsified into mixed micelles. 
Transport of the FFA into enterocytes across the brush border membrane occurs through both 
active protein receptor-mediated transport and passive processes, where long- and medium-
length chain fatty acids are more dependent on transport, while short-chain fatty acids diffuse 
more easily. The most important transporters for fatty acids on the luminal side of enterocytes 
are CD36 and fatty acid transport protein 4 (FATP4), while fatty acid binding protein (FABP) 
is important for enriching FFAs at the cell membrane and organizing absorbed FFAs in 
enterocytes for further metabolism (56-58). 
Cholesterol is a sterol that is an essential part of human cell membranes as well as the precursor 
for several bioactive molecules such as steroid hormones. Approximately 0.5% of dietary lipids 
are cholesterol. Cholesterol uptake over the brush border membrane in the intestine is primarily 
achieved by the Niemann-Pick C1 like 1 (NPC1L1) protein (59).  Not only dietary cholesterol 
is absorbed, but also cholesterol secreted into the intestinal lumen with bile as part of the 
enterohepatic circulation. 
Once absorbed, FFAs are conjugated to coenzyme A (CoA) to form acyl-CoA esters. In 
sequential steps, the acyl-CoA is re-esterified to MAGs to form diacylglycerols and finally new 
TAGs. Cholesterol is esterified with acyl-CoA to form cholesteryl esters (CE) by the enzyme 
acyl-CoA:cholesterol acyltransferase isoform 2 (ACAT2). While short-chain FFAs may 
diffuse through the enterocyte and enter the circulation, TAG and cholesterol need to be 
packaged into lipoprotein particles to be soluble enough to enter the circulation and to be 
directed for use by tissues throughout the organism. A key enzyme for packaging TAGs and 
CE into lipoprotein particles is microsomal triglyceride transfer protein (MTTP). Lipoprotein 
particles are divided based on density and size, where the chylomicrons produced by 
enterocytes have the lowest density. The protein moiety, made up of different apolipoproteins 
(Apo), also differs between the different lipoprotein particles. The other lipoprotein particles 
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apart from chylomicrons are very low-density lipoprotein (VLDL), low-density lipoprotein 
LDL and high-density lipoprotein (HDL) particles (58, 60). 
Table 1: General features of apolipoprotein particles. TAG, triacylglycerol; CE, cholesteryl ester; C, cholesterol; 
PL, phospholipid (60). 
Lipoprotein Diameter (nm) Apolipoprotein TAG (%) CE (%) C (%) PL (%) Protein (%) 
Chylomicrons 75 - 1200 B-48, C, E 86 3 1 8 2 
VLDL 30 - 80 B-100, C, E 52 14 7 18 8 
LDL 18 - 25 B-100 10 38 8 22 21 
HDL 7.5 - 20 A 5 - 10 14 - 21 3 - 7 19 - 29 33 - 57 
 
3.1.1.1 Chylomicrons 
The main apolipoprotein of chylomicrons is ApoB-48. It is transcribed from the APOB gene, 
which encodes ApoB-100. In human enterocytes, the apolipoprotein B mRNA editing enzyme, 
catalytic polypeptide 1 (Apobec-1) edits the APOB mRNA by changing a single nucleotide, 
which generates a stop codon that truncates the ApoB protein after 48% of the amino acids. 
ApoB-48 is lipidated in the endoplasmic reticulum (ER) by MTTP which loads nascent 
chylomicrons with TAG and CE as well as phospholipids. Unlipidated ApoB-48 is degraded. 
The lipid content of chylomicrons varies, and during the fasted state, chylomicrons with less 
lipids and thus smaller in diameter, are released. In the postprandial state, the TAG loading of 
chylomicrons increases manifold. Nascent chylomicrons then move to the Golgi to mature. 
Apart from the structurally necessary ApoB-48, chylomicrons may acquire a number of 
exchangeable apolipoproteins, such as ApoC. The mature chylomicron is released into the 
lymphatics and, via the thoracic duct, further into the circulation, where it may acquire ApoE 
from other lipoprotein particles such as HDL (61). 
The TAGs of chylomicrons are used by tissues as fuel or for storage in adipocytes. To mobilize 
the lipids from the TAGs in the chylomicrons into the target cells, the fatty acids of the TAGs 
are hydrolysed to FFAs by lipoprotein lipase (LPL). LPL is expressed in cells that utilize FFAs 
as either fuel or storage such as myocytes, cardiomyocytes and adipocytes. Mature LPL is 
transported and attached to the glycocalyx of capillaries in the target tissues (62). Of the 
exchangeable apolipoproteins, Apo-CII is believed to facilitate LPL-mediated lipid uptake, 
while Apo-CI and Apo-CIII are believed to inhibit LPL-mediated uptake (63). The liver has a 
tissue-specific lipase called hepatic lipase that also hydrolyses TAG. As the chylomicron 
becomes increasingly poor in TAG, it is turned in to what is called a chylomicron remnant. The 
chylomicron remnants are cleared from the circulation by the liver, where ApoE binds to 
heparan sulfate proteoglycans to facilitate uptake of the chylomicron remnants by LDL 
receptors (LDLr) and LDL receptor-related protein 1 (LRP1) (61). 
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3.1.1.2 Very low-density lipoprotein particles 
The second largest lipoprotein particle after chylomicrons is VLDL. VLDL is secreted by 
hepatocytes to recirculate TAGs and cholesterol to tissues. Sources of TAG include absorbed 
chylomicron remnants as well as FFAs taken up and re-esterified in the hepatocyte. The FFAs 
come via the portal circulation from the intestine or from FFAs released by adipocytes into the 
circulation during fasting. The majority of the de novo synthesis of cholesterol takes place in 
the liver, while peripheral tissues are mostly dependent on the uptake of cholesterol from 
recirculated lipoprotein particles. The structurally obligate apolipoprotein in VLDL is ApoB-
100 in human as the human liver lacks Apobec-1 and only produces the full-length transcript 
of APOB. Several rodents, including mice and rats, do have active Apobec-1 analogues in liver 
tissue and thus synthesize VLDL containing either ApoB-100 or ApoB-48. The ApoB protein 
is lipidated mainly with TAG but also cholesterol and CE by MTTP in the ER, after which the 
forming VLDL particle is moved to the Golgi apparatus for maturation. VLDL is secreted as 
an approximately 35 to 100 nm diameter lipoprotein particle (64). Similar to chylomicrons, 
VLDL can acquire several different exchangeable apolipoproteins, most notably ApoE and 
species of ApoC (65). 
The TAG in VLDL is used by peripheral tissues in a similar way as the TAG in chylomicrons, 
and LPL plays an important role in successively decreasing VLDL size and TAG content by 
hydrolysis, increasing the density and proportion of cholesterol in the lipoprotein particle. As 
the density increases and size decreases, the VLDL turns in to what is termed an intermediate 
density lipoprotein particle, and eventually, as the density increases, an LDL particle.  
3.1.1.3 Low-density lipoprotein particles 
As the VLDL particle is transformed into an LDL particle, it loses in most cases its 
exchangeable apolipoproteins, leaving the majority of LDL particles with only ApoB. The 
main lipid in LDL is CE, and, in humans, the majority of cholesterol in the circulation is found 
in the LDL fraction. The LDL particle is taken up via LDLr by receptor-mediated endocytosis. 
Mutations in the LDLr gene are the most common cause of familial hypercholesterolaemia 
(FH) (66), a class of conditions associated with greatly elevated serum cholesterol and 
increased CVD, and the study of FH has been pivotal in understanding the importance of LDL 
and LDLr in cholesterol metabolism and vascular health. The ApoB of LDL binds to LDLr and 
induces clathrin-dependent endocytosis. Acidification of the endosome causes a 
conformational change in the LDLr which releases the LDL particle. The LDL particle is 
degraded allowing for the use of carried cholesterol, and ApoB is broken down into amino 
acids. The LDLr is recycled and recirculated to the cell membrane. After mutations in 
proprotein convertase subtilisin/kexin type 9a (PCSK9) were proven to strongly influence 
plasma cholesterol (67), it was found that PCSK9 inhibits the recirculation of LDLr and instead 
targets the receptor for degradation, by inhibiting the conformational change in the endosome 
(60, 68). 
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3.1.1.4 High-density lipoprotein particles 
Cholesterol transport out to peripheral tissues is managed by LDL. Transport of cholesterol 
from the periphery to the liver, so-called reverse cholesterol transport, is conducted by HDL. 
The major apolipoprotein of HDL is ApoA-I which is produced mainly by the liver and 
intestine (60, 69). In contrast to chylomicrons and VLDL, which are secreted as mature 
particles, ApoA-I is secreted not fully lipidated and mainly loaded with phospholipids as a 
nascent HDL, and maturation occurs in the circulation through interaction with other 
lipoproteins. The regulation of ApoA-I synthesis is mainly transcriptional, and several 
mediators have been shown to affect ApoA-I secretion such as dietary fat, niacin, alcohol, 
androgens, oestrogens, glucocorticoids and statins. While ApoA-I is the most abundant 
apolipoprotein in HDL, it has the ability to acquire several other exchangeable apolipoproteins, 
such as ApoA-II, ApoE, ApoC species and other less common proteins.  
Several processes contribute to loading HDL with lipids to form mature HDL. The cholesterol 
efflux protein ATP-binding cassette transporter A1 (ABCA1) is one of the main exporters of 
cholesterol from peripheral cells, and ABCA1 binds ApoA-1 and allows for HDL uptake of 
cholesterol from tissues. Free cholesterol that is taken up from membranes and via ABCA1 is 
esterified by the enzyme lecithin-cholesterol acyl-transfer (LCAT) which is bound to HDL 
particles. Cholesteryl ester transfer protein (CETP) is a soluble enzyme present in human 
plasma secreted by the liver and the intestine. CETP mediates an exchange where HDL delivers 
CE to VLDL and LDL and gets TAG in return. This flux of CE back to VLDL and LDL caused 
high interest in CETP inhibition as a potential therapeutic avenue to lower the risk for CVD. 
However, clinical trials have failed to deliver positive results, and indeed, an increase in 
cardiovascular death is seen (70). The final uptake of HDL content in the circulation is mainly 
done in the liver, where HDL cholesterol is taken up via scavenger receptor class B type I (SR-
BI). The receptor mediating complete particle uptake is still not known. SR-BI also seems to 
play a role in macrophage cholesterol efflux, together with ABCA1 and ATP-binding cassette 
transporter G1 (ABCG1) (69). 
3.1.2 Fatty acid metabolism 
Apart from being absorbed from the diet by the intestine, several cell types have the capability 
of synthesizing fatty acids, and most fatty acid synthesis takes place in the liver and adipocytes. 
The substrate for fatty acid synthesis is acetyl-CoA, generated by, for example, carbohydrate 
metabolism. Acetyl CoA carboxylase (ACC) catalyses the committing step of fatty acid 
synthesis by carboxylation of acetyl-CoA to malonyl-CoA (60). Subsequent elongation of the 
carbon chain is carried out by a multiunit enzyme in mammals called fatty acid synthase (FAS) 
restricted to the cytosol.  
Fatty acid synthesis is regulated by the transcription factor sterol response element binding 
protein (SREBP) 1 (71). There are two genes encoding SREBPs: SREBF1 coding for the two 
isoforms SREBP-1a and SREBP-1c, and SREBF2 coding for SREBP-2. The isoform SREBP-
1a is expressed at much lower levels, in the liver by almost a factor of 10 times less than isoform 
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1c, however, it is more widely distributed being the most prevalent form in certain 
metabolically inactive tissues. Being a much more potent transcription factor than 1c, isoform 
1a upregulates FAS mRNA expression greater than 4 times more than 1c, and 1a also has a 
more pronounced effect on sterol synthesis than 1c (72, 73). SREBP-1c is mainly responsible 
for regulating fatty acid synthesis in liver and metabolically active tissue, while SREBP-2 
regulates sterol metabolism.  
To ensure separation of the synthetic and degrading pathways, degradation of fatty acids takes 
place in the mitochondrial matrix. Long-chain fatty acids are transported into the 
mitochondrion via carnitine shuttles, where they are degraded by β-oxidation (60), yielding 
acetyl-CoA that can be used for energy or in the generation of ketone bodies. 
3.1.3 Cholesterol metabolism 
Cholesterol is used by all cells in the body as part of the cell membrane. Specialized cells also 
use cholesterol for steroid hormone synthesis. A subject maintaining a normal Nordic diet 
absorbs approximately 250 – 350 mg of cholesterol from dietary intake per day. Endogenous 
synthesis of cholesterol however, normally supplies approximately 1 g of cholesterol per day 
(55). The balance of intake and synthesis is closely regulated, and increased intake results in 
lower synthesis. The substrate of cholesterol synthesis is acetyl-CoA, and the committed step 
of the pathway is the formation of mevalonate from 3-hydroxy-3-methylglutaryl-CoA (HMG-
CoA) catalysed by the enzyme HMG-CoA reductase (HMGCR), the inhibition of which is the 
pharmacological target of statins. Via the intermediates geranyl pyrophosphate, farnesyl 
pyrophosphate and squalene, cholesterol is formed (60).  
The regulation of cell cholesterol homeostasis is carried out by SREBP-2. SREBP-2 acts as a 
sensor for cholesterol availability, and in conditions with low levels of cholesterol in the 
membrane, the basic-helix-loop-helix-leucine zipper protein SREBP-2 is cleaved by site-1-
protease (S1P) and transported to the Golgi by a protein known as Scap. In the Golgi, site-2-
protease (S2P) cleaves off the DNA binding domain of SREBP-2 that translocates to the 
nucleus and binds to sterol response elements (SREs), promoting gene transcription (74, 75). 
During periods of adequate sterol levels, membrane cholesterol causes Scap to undergo 
conformational change, allowing the binding of the protein “insulin induced gene” (INSIG) 
which in turn binds Scap to SREBP, inhibiting cleavage and translocation to the Golgi. Not 
only is the transcription of HMGCR and enzymes involved in cholesterol synthesis regulated 
by SREs, but several proteins regulating the cell sterol concentration are also induced by 
SREBP-2, such as LDLr. Curiously, even PCSK9, while normally causing a decrease in 
cholesterol influx by increasing LDLr degradation, is also upregulated by SREBP-2 activation. 
Cholesterol cannot be degraded in the body but has to be excreted via bile, either as cholesterol 
or as part of bile acids and bile salts. The hepatocytes secrete bile into canaliculi, and free 
cholesterol can be secreted into the bile, a process that is regulated by the NPC1L1 receptor 
that mediates reabsorption to hepatocytes (76). Cholesterol and bile components may then be 
reabsorbed in the intestine as part of the enterohepatic circulation of sterols. 
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3.2 TRYPTOPHAN METABOLISM 
Tryptophan (Trp) is the least abundant of all amino acids and a prerequisite for all lifeforms. 
While certain plants and prokaryotes are able to synthesize Trp de novo, mammals must acquire 
it through the diet (77). Apart from being used in protein synthesis, tryptophan is metabolized 
along two main pathways. Tryptophan hydroxylase carries out the reaction forming 5-
hydroxytryptophan from Trp, which can then be further modified by aromatic amino acid 
decarboxylase to serotonine (5-hydroxytryptamine; 5-HT) (60). 5-HT is an important 
neurotransmitter in both the CNS and the enteric nervous system but also conveys signals in 
mast cells and platelets. Through the actions of serotonin-N-acetyl transferase and acetyl-
serotonin O-methyltransferase, 5-HT can be metabolized to melatonin, primarily in parts of the 
CNS regulating sleep, such as the pineal gland. However, only approximately 1% of Trp is 
metabolized to 5-HT and melatonin, while 95% of Trp is metabolized along what is commonly 
called the kynurenine pathway.  
3.2.1 The kynurenine pathway   
The initial and rate-limiting step of the kynurenine pathway is the cleavage of Trp by one of 
two haem-dependent dioxygenases, tryptophan 2,3-dioxygenase (TDO) and indoleamine 2,3-
dioxygenase (IDO), which exists in two isoforms, IDO1 and IDO2. TDO is mainly expressed 
in the liver with less pronounced expression in the gastrointestinal tract, brain and bone marrow 
(78-80). TDO in the liver metabolizes the quantitatively largest portion of Trp, approximately 
90% of oxidized Trp (81), and liver TDO functions as a regulator of plasma Trp concentration, 
degrading excess ingested Trp that is neurotoxic in high concentrations (82). Of the 
dioxygenases, TDO has the highest specificity for Trp, is induced by glucocorticoids and 
stabilized by the availability of Trp (77) and is inhibited by feedback inhibition by protonated 
nicotinamide adenine dinucleotide phosphate (NADPH) (81).  
While TDO is concentrated in the liver, IDO expression is more ubiquitous and expression is 
seen in the kidney, liver, both the male and female reproductive systems, and in immune cells 
and is likely to be inducible in several other tissues and cell types. In contrast to TDO, IDO has 
little influence on systemic Trp levels during basal conditions (81, 83). However, under 
inflammatory conditions, IDO transcription is greatly increased, the main inducer being INF-γ 
with INF-α exhibiting a less pronounced effect. Other pro-inflammatory cytokines such as 
TNF, IL-1β and IL-2, potentiate INF-γ-mediated IDO induction while mediators of resolution 
and tolerance, such as NO, TGF-β and IL-10, inhibit IDO induction by INF-γ (81).  
Trp is cleaved by TDO or IDO into N-formylkynurenine, which is further metabolized to 
kynurenine (Kyn) by the enzyme N-formylkynurenine formamidase. Kyn can be modified to 
kynurenic acid (KynA) by one of four kynurenine aminotransferases (KYAT 1 - 4). KynA is 
an end product of the Kyn pathway, and its formation is irreversible. However, under normal 
conditions, the KYATs have a high KM of approximately 4.7 mM for the reaction of Kyn to 
KynA, and other pathways of Kyn processing are favoured. In the main Kyn metabolizing 
pathway, Kyn can be metabolized to 3-hydroxykynurenine by kynurenine monooxygenase 
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(KMO) and then further to 3-hydroxyanthranilic acid (3-HAA) by the enzyme kynureninase 
(KYNU).  
As an optional pathway to generate 3-HAA from Kyn, it may be transformed to anthranilic 
acid by KYNU, which can then be modified to 3-HAA by KMO. 3-HAA is then quickly 
degraded by the most active enzyme in the Kyn pathway, 3-hydroxyanthranilic acid 3,4-
dioxygenase (HAAO), to form 2-amino-3-carboxymuconic acid-6-semialdehyde (ACMS), 
which is decarboxylated by ACMS decarboxylase into 2-aminomuconic-6-semialdehyde 
(AMS). In turn, AMS is metabolized by AMS dehydrogenase into 2-aminomuconic acid which 
can be further metabolized into acetyl-CoA. The Kyn pathway may also serve to generate 
substrate for nicotinamide metabolism. In this branch of the pathway, ACMS undergoes 
cyclization in a non-enzymatic process to form quinolinic acid (QA). QA can then serve as a 
substrate for further nicotinamide adenine dinucleotide (NAD+) generation through the action 
of the enzyme quinolinate phosphoribosyltransferase (QPRT). Finally, the other possible end 
products of the Kyn pathway are picolinic acid (PA), formed from AMS through non-
enzymatic cyclization, and xanthurenic acid (XA), formed from 3-hydroxykynurenine by 
KYAT (81) (Figure 1). 
3.2.2 IDO as an immune modulator 
When IDO was first described in the 1960s, the discoverers Hayaishi et al. connected IDO to 
immune function and soon discovered the strong upregulation by INF-γ (84, 85). However, it 
was not until Mellor and Munn et al. proved that IDO was integral for immune tolerance of 
allogeneic concepti in mice, and that inhibition of IDO with the pharmacological inhibitor 1-
methyl-tryptophan (1-MT) caused rejection of the concepti, that research into the potential 
immunomodulatory properties of IDO received more widespread attention (86). The rejection 
of allogeneic concepti upon 1-MT treatment was already in the early experiments found to be 
T cell dependent. DCs, and in particular tolerogenic DCs expressing the marker CD123, were 
found to have high IDO expression and the capability of inducing T-cell anergy and TReg 
induction, a capability that was lost upon IDO inhibition with 1-MT (87, 88). Conversely, TReg 
cells strongly induce the expression of IDO in APCs in a CTLA-4 dependent manner, forming 
a positive feedback loop (89). 
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Figure 1. The metabolism of tryptophan. A small portion of tryptophan is metabolized to serotonin and melatonin 
(right), while the quantitatively largest portion of tryptophan in humans is metabolized along the kynurenine 
pathway (left). Enzymes are denoted in italics. Purple outlines the serotonin branch of metabolism and green the 
common part of the kynurenine pathway. The red box outlines the kynurenic acid branch of the kynurenine 
pathway while the yellow box outlines the quinolinic branch. MAO, monoamine oxidase; 5-HIAA, 5-
hydroxyindoleacetic acid; TDO, tryptophan 2,3-dioxygenase; IDO, idoleamine 2,3-dioxygenase; KYAT, 
kynurenine aminotransferase; KMO, kynurenine monooxygenase; KYAT, kynureninase; ACMSD, 2-amino-3-
carboxymuconic acid-6-semialdehyde dehydrogenase; AMSD, 2-aminomuconic-6-semialdehyde dehydrogenase; 
NAD+, nicotinamide adenine dinucleotide. 
The kinase general control nonderepressible 2 (GCN2) is part of a cell protective system called 
the integrated stress response (ISR). In conditions of amino acid starvation, GCN2 is activated 
by empty tRNA, which leads to the phosphorylation of eukaryote initiation factor 2 subunit α 
(eIF2α) that in turn regulates protein synthesis and inhibits mRNA translation (90). Under 
inflammatory conditions, the induction of IDO by INF-γ and other cytokines causes a local 
  23 
depletion of Trp. T cells are sensitive to GCN2 activation, responding with anergy. Activation 
of GCN2 by low Trp availability is believed to be a major mechanism by which IDO activity 
regulates T-cell responses (91). Interestingly, IDO consumption of Trp is mainly believed to 
occur in innate immune cells, e.g., plasmacytoid DCs.  
The response to GCN2 activation in immune cells other than T cells is less well studied, and 
reports of GCN2 effects in macrophages point to an increased IL-6 response upon IDO-
mediated GCN2 activation, and monocyte GCN2-depleted mice suffer increased lethality in 
experimental endotoxaemia (92). In addition to activating GCN2, Trp depletion may stimulate 
other metabolic sensors influencing the immune response, and it is known that IDO activation 
inhibits the mammalian target of Rapamycin (mTOR) and protein kinase C isoform θ (PKC-θ) 
by depleting Trp (93). The immune-modifying ability of IDO has been shown to be protective 
in several models of autoimmune disease, such as experimental autoimmune encephalitis (94), 
colitis (95), rheumatoid arthritis (96) and renal disease (97, 98). While beneficial in settings of 
autoimmunity and inflammatory disease, most human cancer types display an upregulation of 
IDO that mediates tumour immune escape (99). The IDO inhibitor 1-MT, and most often the 
D-isomer clinically named Indoximod, has been used in clinical trials as an adjuvant to cancer 
therapy with varying results (100). 
3.2.3 Kynurenine metabolites 
Several of the downstream metabolites of Trp have been shown to exert potent biological 
effects. KynA is a known agonist of the aryl hydrocarbon receptor (AhR) (101) and of GPR35 
(102). AhR is a basic helix-loop-helix transcription factor that, during resting conditions, is 
bound to chaperones and inactive in the cytosol. Upon ligation of the receptor, AhR translocates 
to the nucleus and binds to dioxin response elements (DREs) in the DNA. The first known 
ligand of AhR was the irritant 2,3,7,8-tetrachlorodibenzo-p-dioxin, and AhR signalling was 
implicated in the response to noxious foreign substances (103). However, AhR is expressed at 
a particularly high level in the immune system and has been found to interact with several other 
pathways, including suppressing NF-κB action in macrophages (104).  
The role of KynA in immune reactions is debated, and both suppressive and stimulatory effects 
are described. Treatment with KynA in vitro during unstimulated conditions has, for example, 
been shown to both increase (101, 105) and decrease (106) IL-6 secretion in different cell lines. 
KynA has also been implicated in the infiltration of neutrophils into the vascular wall (107). 
After stimulation, however, KynA has a more consistent immunosuppressive effect, for 
example, by inhibiting the secretion of pro-inflammatory cytokines such as TNF (108, 109).  
In the CNS, KynA has long been known to have an effect on neurotransmission, particularly 
as an antagonist of the N-methyl-D-aspartate (NMDA) glutamate receptor (110). In a set of 
elegant experiments, Agudelo et al. demonstrated that exercise training induced KYAT activity 
and subsequent peripheral KynA synthesis, which led to a decreased expression of pro-
inflammatory markers in the CNS and provided a molecular mechanism for the beneficial 
effects seen by exercise training in depression (111). In more recent work, the same research 
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group demonstrated that KynA, through the action of GPR35, increased the energy expenditure 
in mice, decreased white adipose tissue mass, and transformed adipose tissue into having a 
metabolically more favourable profile with increased expression of uncoupling protein 1. 
Furthermore, the adipose tissue of treated mice showed signs of decreased inflammation with 
the expression of genes connected to M2-type like macrophages and TReg cells (112). 
Another Kyn metabolite with strong bioactivity is 3-HAA. Treatment with 3-HAA induces T-
cell apoptosis in a caspase-8 dependent manner (113). The balance between T-cell subsets is 
seen to shift upon 3-HAA treatment with an increase in TReg cells (114). Although the exact 
mechanism of 3-HAA action is not fully known, it has been suggested that 3-HAA inhibits 3-
phosphoinositide-dependent protein kinase 1 (PDPK1), thus inhibiting NF-κB activation and 
interfering with TCR activation, leading to TH cell anergy and apoptosis (115). Other suggested 
mechanisms are related to redox balance, and 3-HAA has been suggested to deplete 
intracellular glutathione (GSH) in activated T cells and to induce the expression of 
haemoxygenase-1 (116, 117). Additionally, monocyte cell lines have been shown to respond 
to 3-HAA with apoptosis, although at higher treatment concentrations (118).  
3.3 GLYCOLYSIS AND OXIDATIVE PHOSPHORYLATION 
A steady supply of energy, carried in the form of ATP, is necessary for cell survival. Central 
to the generation of ATP is the metabolism of carbohydrates and the process of glucose 
degradation by glycolysis. The resulting metabolites may be used in a series of reactions known 
as the citric acid cycle (TCA), which provides fuel for mitochondrial oxidative 
phosphorylation, a process generating large amounts of ATP. However, several metabolites of 
glycolysis or TCA are necessary as materials for biomolecule synthesis while others have 
signalling functions. It is clear that both glycolysis and oxidative phosphorylation have several 
other functions beyond the generation of energy. 
3.3.1 Glycolysis 
Glycolysis is the generation of two molecules of pyruvate from one molecule of glucose 
through a series of reactions with a net result of two molecules of ATP generated in the process 
(60). The pathway is evolutionally conserved, and both prokaryotic and eukaryotic cells 
perform glycolysis. Glucose may enter the cell through glucose transporters (GLUTs), with 
different tissue distributions. Insulin sensitive GLUT-4 is abundant in muscle while a wide 
array of GLUTs are present on immune cells and, TH cells are dependent on GLUT-1 function 
(119). Once in the cell, glucose is trapped after phosphorylation by hexokinase, isomerized to 
fructose and then phosphorylated again in the rate-limiting step of glycolysis by 
phosphofructokinase. The six-carbon sugar is then cleaved into two three-carbon compounds, 
dihydroxyacetone phosphate and glyceraldehyde-3-phosphate. Thus far, glycolysis requires 
energy, and two molecules of ATP are spent. The two generated three-carbon compounds can 
be further metabolized to pyruvate, generating 2 molecules of ATP each, making the sum of 
ATP gained from running one glucose molecule through glycolysis 2 ATP. In tissues with a 
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high ratio of NADH to NAD+, such as during hypoxic conditions, or in cells lacking 
mitochondria, pyruvate is reduced to lactate. 
Glycolysis is tightly regulated and several metabolites function as negative feedback loops, 
such as phosphorylated glucose, which inhibits hexokinase and a high ATP to adenosine 
monophosphate (AMP) ratio, which inhibits phosphofructokinase. Hormonal regulation of 
glycolysis by insulin and glucagon also plays major regulatory roles. Interestingly, the 
transcription factor hypoxia-induced factor 1α (HIF-1α) has emerged as a potent inducer of 
glycolysis (120). 
3.3.2 The citric acid cycle and oxidative phosphorylation 
While the production of two molecules of lactate from one glucose molecule yields two ATP, 
an alternative path for the generation of large quantities of ATP would be for the pyruvate to 
enter the TCA and eventually be oxidized to CO2 and water, fuelling ATP generation through 
oxidative phosphorylation (OXPHOS). The complete oxidation of glucose yields 
approximately 30 molecules of ATP, the majority of which, 26 molecules, are generated during 
OXPHOS (60). TCA takes place in the mitochondria, and pyruvate is transported into the 
mitochondrion by specific transporters. The committed and irreversible step of entry into the 
TCA cycle is the decarboxylation of pyruvate to acetyl-CoA by the pyruvate dehydrogenase 
(PDH) complex. PDH is tightly regulated, in part by feedback inhibition, and both acetyl-CoA 
and NADH inhibit PDH activity. However, the key regulatory process is inhibition of PDH 
due to phosphorylation by the enzyme pyruvate dehydrogenase kinase (PDK).  
There are four isoforms of PDKs with slightly different tissue distributions where PDK2 and 
PDK4 are the most widely distributed and PDK1 and PDK3 are less common (121). PDK is 
an important switch, as PDH activity not only regulates the formation of lactate but also the 
shift between glycolysis and fatty acid oxidation as being the source for substrate in the TCA. 
Peroxisome proliferator-activated receptor γ (PPARγ) coactivator 1 (PGC-1) and activation of 
the glucocorticoid receptor are both known to induce the expression of PDK4, while insulin 
seems to downregulate PDK4 expression (122, 123). Several pharmacological inhibitors of 
PDK exist, with one of the most thoroughly investigated being the small molecule 
dichloroacetate (DCA), which effectively inhibits PDK activity (124). Several studies have 
been conducted with DCA, mainly reprogramming the metabolic profile of cancer cells (124, 
125).   
TCA is a set of reactions where the two-carbon unit acetyl-CoA is completely oxidized to CO2 
and H2O (Figure 2). Intermediate steps include the metabolism of citrate, isocitrate, α-
ketoglutarate, succinyl-CoA, succinate, fumarate, malate and oxaloacetate. Several of the 
intermediates are important biomolecules. Succinate has been shown to have immune-
activating properties by stimulating IL-1β release (120). GPR91 has been shown to be 
selectively ligated by succinate (126), and succinate signalling through GPR91 has been argued 
to promote pro-inflammatory mechanisms and activate innate immune responses (127, 128).  
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Figure 2. Glycolysis and the citric acid cycle. Glucose is metabolized in the glycolysis to pyruvate. Pyruvate may 
either enter the citric acid cycle or be used as substrate for lactate production. Dichloroacetate inhibits pyruvate 
dehydrogenase kinase, which in turn inhibits pyruvate dehydrogenase complex, the enzyme responsible for 
metabolizing pyruvate to acetyl-CoA. TCA, citric acid cycle; DCA, dichloroacetate; CoA, co-enzyme A. 
3.3.3 The Warburg effect 
The cellular metabolic switch to glycolysis and the formation of lactate during conditions of 
restricted oxygen is widely known and termed anaerobic glycolysis. However, in 1926 Otto 
Warburg et al. published the observation that tumours rely on glycolysis and lactate formation 
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even during normoxia (129). This phenomenon of a preference for glycolysis and lactate 
formation over OXPHOS during normoxia is referred to as aerobic glycolysis or the Warburg 
effect. It is prevalent in rapidly dividing and metabolically active cells, such as tumour cells or 
activated immune cells. The rationale for using the less efficient way of generating ATP, 
glycolysis, over OXPHOS is the need for biomolecules to form new nucleic acids, membranes 
and organelles (130). Active glycolysis favours the intake of glucose and increases the 
availability of intermediate metabolites. Indeed, a clear dichotomy can be seen in immune cells 
where naïve lymphocytes, TReg cells, and M2-like macrophages employ OXPHOS while 
activated T cells and M1-like macrophages activate glycolysis (131, 132). The metabolism of 
Trp by IDO has the ability to shift T-cell metabolism towards increased OXPHOS, possibly 
through the action of GCN2 (133, 134). 
4 THE ATHEROSCLEROTIC PLAQUE 
The most prominent feature of atherosclerosis and the feature that causes symptoms is the 
atherosclerotic plaque. The initial event of atherosclerotic plaque formation is the retention of 
LDL and ApoB-containing remnant lipoprotein particles in the intimal layer of large- and 
medium-sized arteries (135, 136), a process where proteoglycans seem to play a pivotal role 
(137, 138). Local factors predisposing towards lipoprotein retention and plaque formation are 
low shear stress and turbulent and oscillating flow (139). The mechanisms governing 
lipoprotein uptake in the endothelium are incompletely understood but involve, in part, specific 
receptors such as SR-BI and caveolin-1 (140, 141). Once retained, lipoprotein particles may 
undergo modifications such as aggregation or oxidation, generating highly immunogenic 
oxidized LDL particles (oxLDL) (142, 143). While oxidation improves macrophage uptake of 
the LDL particle and oxLDL is immunogenic, epitopes on native ApoB have also been shown 
to give rise to strong immune responses (144) and clinical trials of antioxidants in 
atherosclerosis have so far not yielded desired results (145-147). 
Retention of lipoprotein particles in the intima activates the endothelium, induces expression 
of adhesion molecules such as vascular adhesion molecule 1 (VCAM-1), and leads to the 
recruitment of immune cells propagating an inflammatory and maladaptive response (148). 
Through the recruitment and proliferation of leukocytes by continuous pro-inflammatory 
processes, the plaque grows.  
Symptoms of atherosclerotic disease arise either when the growing plaque obstructs the lumen 
of the artery to such a degree that distal blood flow is inadequate, as in chronic coronary 
syndromes (CCS; stable angina pectoris) and in peripheral arterial disease of the limbs. 
Alternatively, acute symptoms may arise from plaque rupture, with the exposure of pro-
thrombotic material to the circulation causing an intraluminal thrombus formation that quickly 
obstructs blood flow causing end organ ischaemia. Examples of conditions caused by plaque 
rupture are acute coronary syndromes (ACS) including myocardial infarction in the case of 
plaque rupture in the coronary arteries, stroke when plaque rupture occurs in the carotid or 
intracranial arteries and bowel ischaemia with plaque rupture in mesenteric arteries. 
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Interestingly, the proportion of acute events due to plaque rupture is suggested to be declining, 
while other causes of thrombus formation on atherosclerotic plaques, such as endothelial 
erosion, are increasing, possibly due to increased statin use (149) (Figure 3). 
 
Figure 3. Overview of an atherosclerotic plaque. Low-density lipoproteins are retained in the intima. Immune 
cells such as monocytes, macrophages and T cells are recruited to the site. Macrophages may develop in to lipid 
laden foam cells. Depending on local environmental conditions, both pro-inflammatory cells such as TH1 cells and 
tolerogenic cells such as TReg cells occur in plaques. Smooth muscle cells infiltrate the plaque and form a fibrous 
cap. If the fibrous cap ruptures, thrombogenic material is exposed to the bloodstream and a thrombus may form, 
causing end-organ ischaemia. INF, interferon; TNF, tumour necrosis factor; IL, interleukin; SMC, smooth muscle 
cell. 
4.1 IMMUNE CELLS IN THE ATHEROSCLEROTIC PLAQUE 
Atherosclerosis is a chronic inflammatory disease (3). The initial retention of cholesterol-rich 
lipoprotein particles and endothelial activation recruit mainly monocytes and macrophages 
which are the most prominent cells of the atherosclerotic plaque. Macrophages in 
atherosclerotic plaques originate both from differentiated monocytes recruited from the 
circulation and the proliferation of local macrophages, with the latter being the predominant 
factor (150). Plaque macrophages take up oxidized and native LDL, in part by scavenger 
receptors such as CD36 (151) and SR-A (152). The loading of macrophages with modified 
LDL saturates the cytoplasm with cholesterol, turning the macrophages into “foam cells”, 
hallmark cells of fatty streaks and atherosclerotic plaques (153). The importance of scavenger 
receptors such as CD36 in vivo has, however, been questioned, as results from experiments in 
mouse models are not uniform and it has been reported that ApoE -/- CD36 -/- mice have larger 
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lesions than with ApoE-/- mice (154). Furthermore, patients with CD36 deficiency were 
demonstrated to have an increased risk of coronary artery disease (CAD) in a small study (155).  
A factor other than uptake that influences macrophage lipid loading is macrophage cholesterol 
efflux. Important mediators of cholesterol efflux from macrophages to HDL particles are 
ABCA1 and ABCG1, and genetic ablation of these genes in macrophages leads to more severe 
atherosclerosis in mice (156, 157). Another possible mode for cholesterol efflux out of the 
atherosclerotic plaque is the migration of cholesterol-laden macrophages out of the intima, and 
it has been shown that local factors in the plaque prevent macrophages from migrating out, 
trapping them in the plaque (158). The uptake of oxLDL has been shown to induce several 
forms of cell death, including immunologically inert apoptosis, and necrosis and pyroptosis 
which generate immunogenic material (159-161). The accumulation of dead cells and debris, 
in conjunction with impaired macrophage efferocytosis observed in atherosclerotic plaques 
(162), leads to the formation of a necrotic core. 
The loading of macrophages with oxLDL may also activate PRRs. Influx of oxLDL via CD36 
is known to prime the NLRP3 inflammasome by inducing NF-κB (163, 164). Furthermore, the 
accumulation of cholesterol in the cytosol of macrophages leads to the precipitation of 
cholesterol crystals, which are well-known activators of the NLRP3 inflammasome (165). The 
role of the NLRP3 inflammasome in atherosclerosis is underscored by the finding that transfer 
of bone marrow cells genetically ablated for components of the NLRP3 inflammasome (either 
ASC, NLRP3 or IL-1α/β) abolishes plaque formation in Ldlr-/- mice (166). Curiously, the same 
strong effect was not observed in ApoE-/- mice (167). Studies in human cohorts show an 
increase in components of the NLRP3 inflammasome in atherosclerotic plaque material (168). 
The product of inflammasome activation, IL-1β, is also closely linked to atherosclerosis. IL-
1β has been observed in human coronary atherosclerosis, and its expression correlates with the 
severity of disease (169). Mechanistic studies in ApoE-/- mice revealed that blockade or genetic 
ablation of IL-1β decreased fatty streak and plaque formation (170, 171). The final proof of 
concept that IL-1β is a valid target for atherosclerosis treatment came with the CANTOS trial 
in which inhibition of IL-1β by the monoclonal antibody Canakinumab decreased 
cardiovascular events (15). 
Macrophages in atherosclerotic plaques display traits of several different subsets. Pro-
inflammatory and matrix-degrading functions normally associated with an M1-like phenotype 
are associated with worsened disease, and M1-like macrophages have been linked to 
symptomatic plaques both in carotid and coronary arteries (172, 173). The distribution within 
the plaque also points towards a protective role of M2-like macrophages, which are often seen 
in the fibrous cap that prevents rupture, while M1-like macrophages are seen in the rupture-
prone shoulder regions (174). M1-like and M2-like macrophages normally constitute 40% and 
20%, respectively, of macrophages in mouse atherosclerotic lesions, thus allowing for a large 
proportion of less common and atherosclerosis-specific macrophages such as Mox 
macrophages (175).  
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The determining factor for macrophage polarization is the local plaque milieu, where TH1 
cytokines such as INF-γ promote an M1-like phenotype. The two polarizing cytokines M-CSF 
and GM-CSF have been described to play important and partly opposite roles in the vascular 
wall, where the latter is a known M1-like polarizing cytokine while the former is suggested to 
induce a more M2-like phenotype (176, 177). Interestingly, foam cells that normally display 
markers of both M1-like and M2-like phenotypes, are less prone to polarize towards M1-like 
functions compared to non-foamy macrophages, suggesting the uptake of lipids to be a 
protective response (178). 
DCs are found in the vascular wall and more abundantly in atherosclerotic plaques where they 
play an important role (179). In an indirect manner, DCs may affect atherosclerotic plaques by 
lowering plasma cholesterol and increasing lipoprotein clearance via T-cell dependent 
antibody-mediated effects (180). As the main activators of the adaptive immune system, DCs 
are believed to be important in mobilizing T-cell responses in atherosclerotic plaques, and 
genetic ablation of the co-stimulatory molecules CD80/CD86 resulted in decreased early lesion 
formation in Ldlr-/- mice (181). As co-stimulatory molecules are found on several types of 
APCs, the contribution to the phenotype of DCs versus that of macrophages remains to be 
demonstrated.  
A study targeting MyD88, the main adaptor protein involved in TLR activation, in DCs showed 
that the transfer of MyD88-deficient CD11c cells into Ldlr-/- mice resulted in more pronounced 
lesions (182). A likely mechanism causing the increased lesion development would be that 
while MyD88 deficiency inhibited TH1 effector cells, it would also inhibit TReg cells, and 
indeed, a decreased TReg activity was seen in the plaques supporting the notion that TReg 
inhibiting functions outweigh the pro-inflammatory functions of effector T cells in this setting. 
The ability of DCs to shape immune responses has also been suggested as a potential 
therapeutic approach for atherosclerosis with the administration of tolerogenic DCs, for 
example, by taking advantage of the IDO-mediated induction of TReg cells (183). 
In addition to myeloid cells such as macrophages and DCs being common in the plaque, the 
pro-inflammatory environment induces changes in vascular smooth muscle cells (SMCs). 
During the formation of the atherosclerotic plaque, media SMCs infiltrate the growing lesion, 
and are primarily found in the fibrous cap, where they have a stabilizing function. Collagen 
secreted by vascular SMCs improves the mechanical stability of the fibrous cap and the plaque 
while degradation of mature collagen increases vulnerability (184). The pro-inflammatory 
milieu of the atherosclerotic plaque induces vascular SMCs to change to a more myeloid 
phenotype, losing SMC markers and gaining phagocytic abilities (185). 
Adaptive immune responses are highly active in atherosclerotic plaques. T cells are found in 
high proportion, particularly in the fibrous cap and the shoulder region of the plaque 
constituting 22% and 18% of cells at each location (186). An active T-cell response is seen in 
plaque rupture (187). Immunodeficient mice without lymphocytes (scid/scid mice) display a 
dramatic decrease in atherosclerotic plaque formation (188). Depletion of CD4+ cells leads to 
less lesion formation, and the pro-atherogenic effect of CD4+ cells is dependent on the TH1 
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subset (189). Both oxLDL and native LDL are potential sources of epitopes for T cells, and 
while increasing oxidation leads to decreased T-cell reactivity, this may be due to degradation 
of ApoB epitopes by excessive oxidation (143, 190). Aggregation of LDL particles correlates 
with T-cell activation in vitro and is associated with cardiovascular events in humans (191).  
The main cytokine of the TH1 response is INF-γ, which has been demonstrated to aggravate 
atherosclerosis in numerous studies. Deletion of the INF-γ receptor causes a decrease in 
atherosclerosis in both ApoE-/- and Ldlr-/- mice (192, 193), and deletion of the TH1-inducing 
transcription factor Tbet also induces less INF-γ production and less plaque formation (194). 
INF-γ signals mainly via the Janus activated kinase / signal transducer activator of transcription 
1 (JAK/STAT1) pathway, and transfer of STAT1 deficient bone marrow results in reduced 
atherosclerosis in mouse models (195). 
Congruent with the notion that atherosclerosis is a TH1-mediated disease, signs of TH2 activity, 
such as IL-4 and IL-5 production, are found to a much lesser extent than TH1 in atherosclerotic 
plaques (196). The role of TH2 responses in atherosclerosis is debated. While a skewing of the 
immune response towards TH2 could limit detrimental TH1 responses, individual TH2 cytokines 
are shown to have both pro- and anti-atherogenic effects (197-199). Some of the protective 
effects of TH2 cytokines are likely mediated through the generation of a beneficial B cell 
response.  
TH17 cells have been shown to have a highly pro-inflammatory role in several autoimmune 
diseases. The role of TH17 in atherosclerosis is less clear. Hypercholesterolaemic 
atherosclerosis-prone ApoE-/- mice were found to have increased IL-17A, and developed less 
plaque upon treatment with anti-IL-17A antibodies (200). However, IL-17A is important for 
collagen synthesis and confers a TGF-β mediated plaque-stabilizing effect, and blockade of IL-
17A leads to increased plaque vulnerability (201). 
TReg cells are found in small numbers in atherosclerotic plaques but have a potent anti-
atherogenic effect. The number of lesional TReg cells fluctuates with plasma cholesterol in a 
mouse model of atherosclerosis, where prolonged hypercholesterolaemia attenuates TReg 
infiltration (202). The depletion of TReg cells increases atherosclerosis (203), as does depletion 
of the TReg signature cytokine IL-10 in ApoE
-/- mice (204). Genetic ablation of the TReg-secreted 
cytokine TGF-β also leads to larger and more inflamed plaques in mice, while  
TGF-β has a complex role also promoting plaque cellular proliferation (205). In human 
atherosclerosis, there is evidence that TReg cell numbers and functionality are reduced in 
patients with symptomatic coronary atherosclerosis (206), and low CD4+FoxP3+ counts 
increase the risk of myocardial infarction (207). 
B cells were not considered to be of importance in atherosclerosis for a long time. Detection of 
B cells in atherosclerotic plaques is scarce (186); however in advanced plaques follicle-like 
structures, i.e., tertiary lymphoid organs, with aggregations of B cells, develop in the adventitia 
(208). In a set of elegant experiments, Caligiuri et al. demonstrated that splenectomy of ApoE-
/- mice aggravated atherosclerosis but that this outcome could be reversed by adoptive transfer 
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of B cells (209). In seemingly conflicting results however, pharmacological deletion of B cells 
led to a decrease in atherosclerosis (210). In part, contradicting results in the field of B cells in 
atherosclerosis can be attributed to separate B cell subsets having different effects, for example, 
the recently discovered BReg cells have been shown to be protective in atherosclerosis in an IL-
10 dependent manner (211). 
Antibodies against oxLDL have been found in both human and experimental atherosclerotic 
plaques (212) and are thought to clear oxLDL and reduce atherosclerosis. Of particular 
importance for the atheroprotective effect of antibodies are naturally produced IgMs against 
oxLDL produced by B-1 cells and Ldlr-/- mice depleted of IgM show aggravated atherosclerotic 
disease (213). B-cell depletion with anti-CD20 antibody treatment, however, decreased 
atherosclerotic burden in mice, believed to be partially due to a preferential deletion of B-2 
cells, and indeed reconstitution with B-2 but not B-1 abolished the effect of anti-CD20 
treatment (214). In a recent study, the effect of germinal centre derived IgG was studied. With 
abolition of germinal centre IgG production, a decrease in plaque size was observed while SMC 
content was decreased and plaques were more prone to rupture, which further highlights the 
complex role of B cells in atherosclerosis (215). 
4.2 TRYPTOPHAN METABOLISM IN ATHEROSCLEROTIC DISEASE 
As a strong modulator of inflammatory responses, implications of Trp metabolism exist at 
several stages of atherosclerotic disease. The expression and activity of IDO is strongly 
upregulated by INF-γ, a key cytokine in atherosclerosis, and thus, kynurenines have been 
proposed as tools in the diagnosis and prognosis of atherosclerosis. Dysregulation of Trp 
metabolism and the Kyn pathway has been linked to several risk factors for CVD. 
In a Finnish cohort, IDO activity, as measured by the Kyn/Trp ratio, had a positive correlation 
with risk factors for atherosclerosis, such as CRP and parameters of plasma cholesterol (216). 
A univariate correlation with intima-media thickness, an early marker of atherosclerosis, was 
also seen in females; however, when corrected for other risk factors the association was lost. A 
connection has also been made between kynurenine metabolites and type II diabetes mellitus. 
Plasma levels of Kyn, KynA and 3-hydroxykynurenine were elevated in patients with diabetic 
retinopathy (217). In hepatitis C infection, kynurenine metabolism has been suggested to 
correlate with insulin resistance, although a positive correlation was seen with both Trp and 
Kyn, and no correlation was seen with the Kyn/Trp ratio (218). The metabolite XA has been 
suggested to interfere with insulin signalling and synthesis (219) and has been found in elevated 
concentrations in urine in a small study of patients with type II diabetes (220). Additionally, 
KynA has been suggested to inhibit pro-insulin synthesis by islet cells in vitro (221). In the 
setting of type I diabetes mellitus, a disease marked by autoimmune destruction of pancreatic 
beta cells, the metabolism of Trp seems to have a protective effect. In streptozotosin-induced 
experimental type I diabetes, inhibition of IDO aggravated disease (222). IDO induction has 
been observed in human islets as a protective response to INF-γ (223). Taken together, while 
increasing levels are present in the pro-inflammatory setting of type II diabetes, the protective 
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role in type I diabetes speaks for IDO induction being a protective consequence rather than a 
cause of diabetes. 
Kynurenines have been studied in relation to hypertension. Treatment with Kyn relaxed smooth 
muscle tension in porcine arterial rings. Furthermore, after induction of IDO with INF-γ, the 
same effect was observed with Trp, an effect believed to be endothelium dependent but lost 
with concomitant treatment with 1-MT (224). Kyn also reduced blood pressure in hypertensive 
rats. Hypotension is a fatal complication of sepsis, and increased IDO activity was observed in 
septic patients compared to healthy subjects, while IDO activity was also correlated to the need 
for inotrope medication in septic shock (225). In a mouse model of endotoxaemia, IDO 
knockout mice (IDO-/-) were observed to have higher survival, and in human experimental 
endotoxaemia, IDO activity correlated with hypotension (226, 227). KynA has also been 
implicated in the regulation of blood pressure, where injections of KynA in hypertensive rats 
reduced blood pressure, and mutations in the genes encoding KYATs are seen in spontaneously 
hypertensive rats (228, 229). 
Modulation of IDO has been implicated in the regulation of plasma lipids. In an early 
exploratory study of IDO-/- on a BALBc background, a dramatic increase in plasma TAG was 
noted (230). We have shown that treatment of Ldlr-/- mice with the metabolite 3-HAA 
decreases both plasma cholesterol and TAG and provides a more favourable lipoprotein profile 
(231). The mechanism behind this effect is explored in Paper II, while Paper I demonstrates 
effects on plasma lipoproteins by pharmacological IDO inhibition. 
Epidemiological studies have linked IDO activation to atherosclerotic disease. A decrease in 
Trp and an increase in the Kyn/Trp ratio were observed in patients with CAD compared with 
healthy controls (232). In patients with CAD, manifested as CCS, a high Kyn/Trp ratio was 
associated with an elevated risk of cardiovascular events and all-cause mortality, particularly 
in the quartile of patients with the highest Kyn/Trp ratio (233). Furthermore, the same research 
group demonstrated that the Kyn metabolites KynA, 3-hydroxykynurenine, AA and 3-HAA 
correlated with an increased risk of myocardial infarction in patients with CCS, a risk that was 
even more pronounced in those with concomitant diabetes or pre-diabetes (234). The urinary 
Kyn/Trp ratio was found to correlate strongly with both myocardial infarction, major coronary 
events and all-cause mortality, while surprisingly, no correlation was seen with ischaemic 
stroke (235). Additionally, in previously healthy elderly subjects, an elevated Kyn/Trp ratio, 
level of Kyn or level of 3-hydroxykynurenine at baseline predicted future coronary events (236, 
237). KynA has been reported to increase the risk of all-cause mortality or recurrent myocardial 
infarction in a cohort of patients admitted for myocardial infarction (238). One large clinical 
trial connected to Kyn metabolites in CAD has been conducted. Oral treatment with Tranilast, 
a 3-HAA synthetic analogue, was used to prevent restenosis after percutaneous coronary 
intervention. No effect was seen in the primary outcome of death, myocardial infarction or 
revascularization, although a non-significant decrease in myocardial infarction was seen (239). 
While data on IDO activity in relation to stroke development are less clear than coronary 
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atherosclerosis, the Kyn/Trp ratio has been reported to correlate with stroke severity and infarct 
volume (240).  
In an alternative approach by Li et al., the relationship between the Kyn pathway activity and 
CVD was investigated by means of Mendelian randomization. By this approach, IDO activity 
has a protective effect on the development of ischaemic heart disease, and a similar trend was 
seen for stroke (241). Interestingly, a similar trend towards protection was also observed for 
KYAT3. While seemingly contradictory to other epidemiological studies, the result of the 
Mendelian randomization approach strengthens the notion that IDO activity and Kyn 
metabolite levels are elevated in patients with CVD as a consequence rather than a cause of 
disease. Apart from experimental and clinical studies from other fields, a plethora of 
experimental investigations of IDO and Kyn in the vascular system support this notion. Indeed, 
the strong upregulation of IDO and Kyn metabolites upon inflammation as a feedback response 
highlights the need to differentiate the aim of individual studies. Studies aimed at discovering 
biomarkers may not be suitable for drawing conclusions regarding disease cause or 
mechanisms, and vice versa.   
In Paper I, we were the first to describe the effect of pharmacological IDO inhibition on 
atherosclerosis. Shortly after, Cole et al. used genetic ablation of IDO in ApoE-/- mice to show 
similar results of increased atherosclerosis formation and aggravated plaque inflammation 
(242). Treatment of Ldlr-/- mice with 3-HAA reduced atherosclerotic plaque formation, reduced 
both T-cell and macrophage contents in plaques and downregulated T-cell markers in the 
spleen (231). The interplay between IDO-expressing DCs and TReg cell generation has been 
investigated in several publications. IDO-expressing pDCs are responsible for controlling T-
cell proliferation and infiltration into atherosclerotic plaques, an effect that is abrogated by 1-
MT, and inducing TReg cells that inhibit plaque inflammation (243, 244). Treatment of high fat 
diet fed mice expressing human ApoB with DCs loaded with ApoB and polarized with TGF-β 
to induce a tolerogenic phenotype resulted in an increase in arterial IDO, increased TReg cell 
numbers and reduced atherosclerosis and vascular inflammation, possibly through CTLA-4-
mediated mechanisms (183). Surprisingly, one study reported increased IL-10 production and 
decreased atherosclerosis in IDO-/- mice (238). The same research group, however, recently 
published a report investigating the strong effect of gut microbiota on the IDO effect, which 
could provide one possible explanation for the differing results from different laboratories 
(245).  
The effect of Trp metabolism on non-immune vascular cells is important for IDO effects in 
atherosclerosis. Cuffy et al. demonstrated that vascular SMC IDO activity is integral for 
maintaining tunica media immunoprivilege (246). In a model of allografting, they showed that 
during intact IDO function, vascular SMCs prevent lymphocyte infiltration of the media; 
however, this effect is lost upon 1-MT treatment. 3-HAA is suggested to act by inducing 
haemoxygenase-1 expression in endothelial cells by activating the transcription factor NF-E2 
related factor 2, leading to decreased activation of NF-κB and CCL2 secretion by endothelial 
cells (117). 
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4.3 METABOLISM IN ATHEROSCLEROTIC DISEASE 
The fact that cancer cells and activated immune cells such as M1-like macrophages and T 
effector cells have an increased rate of glycolysis and thereby increased glucose consumption 
has routinely been used for the discovery and monitoring of neoplastic and infectious diseases 
by means of positron emission-tomography for a long time. It was noted early that 
atherosclerotic plaques display a positive signal when labelled glucose is used, most commonly 
18F-deoxyglucose (FDG). Support for the inflammatory component of atherosclerotic disease 
and the connection to modified immune metabolism come from FdG imaging studies showing 
that increased glycolytic activity in the spleen and bone marrow is associated with an increased 
risk of future cardiovascular events (247). Investigating the arterial wall and atherosclerotic 
plaque specifically also shows that increased FdG uptake in the carotid artery is associated with 
increased ipsilateral stroke recurrence in patients with stroke, and increased FdG uptake in the 
ascending aorta is associated with subsequent CVD events in a cohort without previous CVD 
(248, 249). These studies demonstrate that not only is the atherosclerotic plaque detectable by 
its specific metabolism but also that the extent of the change to increased glucose metabolism 
is tied to plaque vulnerability. 
Further evidence of an important metabolic component of atherosclerotic disease comes from 
metabolomic profiling of carotid artery plaques. Cluster analysis of metabolomics data 
separated plaques into one cluster containing highly glycolysing, reduced lipid oxidation group 
of plaques and a second group of plaques without increased glycolysis that maintained lipid 
oxidation (250). These two groups were shown to highly correspond to symptomatic and 
asymptomatic plaques, with the symptomatic plaques being the group with increased 
glycolysis. Analysis of individual metabolites revealed a decreased hexose concentration and 
increased lactate in the symptomatic plaques, and increased expression of glycolytic enzymes, 
both pointing towards a shifted metabolism in vulnerable plaques. Experimental data support 
this notion, where the blocking of pathways necessary for glycolysis, such as GLUT1 glucose 
transport, demonstrates a decrease in atherosclerotic burden in ApoE-/- mice (251).  
Metabolic pathways other than glucose metabolism, such as lipid metabolism and lipoproteins, 
are also connected to modulation of the immune response. It is known that a high-cholesterol 
western diet (WD) induces inflammation in Ldlr-/- mice. Through elegant work, Christ et al. 
demonstrated that WD feeding and hyperlipidaemia metabolically reprograms the immune 
system in Ldlr-/- mice, making myeloid cells from WD-treated mice more reactive even long 
after hypercholesterolaemia has subsided (252). This metabolic reprogramming was dependent 
on NLRP3 function. Interestingly, the sterol metabolism regulator SREBP-2 has been shown 
to regulate IL-1β release (253), and SREBP-2 induced in the endothelium has experimentally 
been linked to NLRP3 activation and plaque formation in mice (254), and SREBP-1 has been 
shown to induce NLRP3 in the aorta of atherosclerotic pigs (255). 
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5 AIMS 
The aim of this thesis is to study immunometabolic mechanisms in atherosclerosis, including 
the kynurenine pathway and glucose metabolism. 
The specific aims for the included papers were as follows: 
Paper I:   To determine the role of IDO-mediated Trp metabolism in atherosclerosis. 
Paper II:   To clarify the mechanism by which 3-HAA affects vascular inflammation and 
lipoprotein metabolism. 
Paper III:  To characterize and understand the role of the kynurenine pathway in human 
atherosclerosis. 
Paper IV: To investigate the effect of the metabolic reprogramming of immune cells 
through the inhibition of PDK in atherosclerosis. 
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6 METHODOLOGICAL CONSIDERATIONS 
6.1 MOUSE MODELS IN ATHEROSCLEROSIS 
Mice are widely used in research, and the characteristics of common strains, such as C57Bl/6 
mice are well known and the whole genome has been sequenced. Wild-type mice do not 
develop atherosclerosis, mainly due to their lipoprotein profile being different from humans. 
Mice circulate a majority of their plasma cholesterol in the HDL fraction, while in humans, 
most cholesterol is found in the LDL fraction. The progression in humans from fatty streak to 
complex atherosclerotic plaque takes several decades, much longer than the lifespan of a 
mouse. To develop atherosclerosis, genetic manipulation and modification of the mouse 
lipoprotein profile is necessary. Two knockout mouse strains, ApoE-/- mice (256) and Ldlr-/- 
mice (257), are the most widely used models for atherosclerosis. The use of mouse models 
offers several advantages to mechanistic research, including well-established inbreeding, 
which reduces experimental variability, fast reproductive cycles and the option to perform 
mechanistic experiments that would not be technically possible or ethically feasible in humans.  
ApoE-/- mice develop hypercholesterolaemia, mainly due to inhibited clearance of 
chylomicrons, VLDL and intermediate lipoprotein particles. Thus, a majority of cholesterol in 
ApoE-/- mice is found in these lipoprotein fractions. Plaque development in ApoE-/- mice occurs 
even on a chow diet; however, atherogenesis can be accelerated by feeding a high-cholesterol 
diet. The distribution of plaque formation follows the distribution seen in humans, with sites of 
turbulent flow such as the minor curvature of the aorta being more affected. The development 
of atherosclerotic plaques in ApoE-/- mice goes through all stages of development found in 
humans, from fatty streak to fibrous or complex plaques with necrotic cores. The most 
prominent difference between rodent disease and human atherosclerosis is that plaques in mice 
do not rupture spontaneously. Another drawback of the ApoE-/- mouse model is that myeloid 
cells with intact ApoE synthesis secrete enough ApoE to mitigate hypercholesterolaemia, thus 
limiting the use of ApoE-/- mice in bone marrow transfer experiments. 
Deletion of Ldlr in mice also induces hypercholesterolaemia, due to reduced clearance of 
VLDL and LDL from the circulation. The hypercholesterolaemia of Ldlr-/- mice is, however, 
not as pronounced as that in ApoE-/- mice, and Ldlr-/- mice display an approximate doubling of 
plasma cholesterol compared to wild-type mice. Lipoprotein profiles of Ldlr-/- mice are more 
similar to the situation seen in most humans, with more cholesterol found in the LDL fraction. 
Fed a chow diet, Ldlr-/- mice do only develop fatty streaks and occasionally very early 
atherosclerotic lesions. On a high-fat and high-cholesterol diet, Ldlr-/- mice develop plaques at 
sites similar to human atherosclerosis, and while complex plaques are seen, progression of 
lesions is not as pronounced as that seen in ApoE-/- mice. Similar to ApoE-/- mice, the plaques 
do not rupture spontaneously. The deletion of Ldlr complicates the study of metabolic 
processes that potentially involve the uptake and binding of LDL particles. 
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In Paper I, ApoE-/- mice were used to study the role of IDO in vascular inflammation and 
atherosclerotic plaque development. For Paper II, Ldlr-/- mice were used. In Paper IV, ApoE-
/- mice were used, and in Paper III, only wild type C57Bl/6 mice were used. 
6.2 PATIENT COHORT 
Human blood, tissues, plaque mRNA data and proteomics data from the Biobank of Karolinska 
Endarterectomies (BiKE) were used in Paper III and Paper IV. The biobank enrols patients 
who undergo endarterectomy of atherosclerotic plaques in the carotid artery due to 
symptomatic (minor stroke, transient ischaemic attack or amaurosis fugax) and asymptomatic 
high-grade stenosis according to the North American Symptomatic Carotid Endarterectomy 
Trial (NASCET) (258). BiKE encompasses plaque material, plasma samples both locally from 
the plaque and from peripheral sites, and patient clinical data. Snap-frozen plaque material that 
was processed and then purified for mRNA assessed by chip array was evaluated for gene 
expression in Paper III, along with plasma and sections of paraffin embedded plaque tissue. 
In Paper IV, plaque material retrieved from BiKE was used for proteomic evaluation, and 
fresh plaque tissue was cultured for in vitro assays. 
6.3 EVALUATION OF EXPERIMENTAL ATHEROSCLEROSIS 
Experimental atherosclerosis was quantified using two methods. In Paper I, Paper II and 
Paper IV en face staining of thoracic aorta with Sudan IV was used, with subsequent 
quantification of the stained area by manual measurement using the ImageJ software. Plaque 
quantification was also carried out in the aortic root, the most proximal part of the ascending 
aorta. Frozen sagittal sections of the first 800 µm of the aorta were stained for lipid content 
with Oil Red O, and the stained area was quantified manually on digital micrograph images for 
each level of the aorta. Evaluation of plaque composition, stability and inflammation was 
performed by immunohistochemistry staining of frozen aortic root sections for vascular and 
immune cells, such as CD68+ macrophages, CD4+ T cells, alpha smooth muscle actin-
expressing SMCs, and VCAM-1. 
6.4 LIPOPROTEIN PROFILES 
Lipoprotein profiles were determined from mouse plasma after fractionation by size exclusion 
fast protein liquid chromatography (FPLC). Detection of total cholesterol and TAG in the 
fractionated material was performed by colourimetric reactions from commercially available 
kits. Profiles of ApoB-containing lipoproteins secreted by HepG2 cells were analysed in cell 
supernatant. The collected supernatant was concentrated by centrifugation in filter centrifuge 
units before fractionation by FPLC. Detection of ApoB-containing lipoprotein particles was 
carried out by enzyme-linked immunosorbent assay (ELISA).  
6.5 STATISTICAL ANALYSIS 
To analyse data where a Gaussian normal distribution could not be assumed, the Mann-
Whitney U-test was carried out to determine the statistical significance of differences between 
two groups. In instances with more than two groups, Kruskal-Wallis one-way analysis of 
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variance with Dunn’s multiple comparisons post hoc test was performed. Correlations between 
two variables that could not be assumed to have a normal distribution were assessed by 
Spearman’s rank correlation coefficient (Paper I and Paper II). The statistical significance of 
differences between two groups with a normal distribution was calculated by paired or unpaired 
Student’s t-test. Linear correlation between two normally distributed variables was presented 
as the Pearson linear correlation coefficient. In Paper III, a binary logistic regression model 
was produced to evaluate the effect of gene expression on symptoms from carotid 
atherosclerotic plaques. Where correction for multiple comparisons was indicated, the 
Bonferroni method of correction was used. Acceptable type I error was set at 0.05 (5%), and 
in the planning of animal experiments, the type II error was set to 0.8 (80%). All statistical 
calculations were performed with either GraphPad Prism (GraphPad Software Inc., USA) or 
SPSS (version 26.0.0, IBM Corporation, USA). 
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7 RESULTS AND DISCUSSION 
7.1 IDO-MEDIATED TRYPTOPHAN METABOLISM REGULATES 
ATHEROSCLEROSIS FORMATION 
In Paper I, we investigated the effects of IDO activity on atherosclerosis formation. Ample 
evidence existed, both from experimental studies and other inflammatory diseases where IDO 
had a protective role, as well as epidemiological data that linked IDO to CVD events. A 
pharmacological approach was used in which the IDO inhibitor 1-MT was administered in 
drinking water to ApoE-/- mice fed a western diet.  
Inhibition of IDO aggravated atherosclerotic disease and plaque formation in ApoE-/- mice both 
in the aortic arch and the aortic root. Mice treated with 1-MT had more CD68+ macrophage 
infiltration into the plaques and expressed more VCAM-1. Expression of the pro-inflammatory 
cytokines CCL2, CXCL10 and TNF was increased in the aortas of treated mice. Surprisingly, 
a strong upregulation of VCAM-1 was seen not only in the plaque but also in the tunica media 
of treated mice, and medial VCAM-1 expression correlated strongly with plaque size. Only 
modest changes in plasma lipids were seen, particularly a decrease in HDL cholesterol.  
We had previously shown that administration of the Kyn metabolite 3-HAA protected against 
atherosclerosis and reduced inflammation (231). In an attempt to reverse the effects seen with 
1-MT treatment, a second experiment was run in which 1-MT-treated mice were given back 3-
HAA or vehicle via intraperitoneal injection. Simultaneous treatment with  
3-HAA completely reversed the effect of 1-MT treatment on lesion size, CD68+ macrophage 
infiltration and VCAM-1 expression both in plaques and in the media.  
As a result of the observed increase in VCAM-1 in the media in IDO-inhibited mice, an in vitro 
system with human coronary SMCs was set up to further investigate the effects of IDO 
inhibition on SMCs. The cultured human SMCs displayed a similar upregulation of the 
VCAM-1 response to INF-γ stimulation with 1-MT treatment as that observed in vivo. 
Treatment of the cultured cells with 3-HAA inhibited the effect of 1-MT. 
Activation of the endothelium and expression of cellular adhesion molecules such as  
VCAM-1 is an early step in atherosclerosis development and is necessary for the recruitment 
of immune cells into the forming plaque (148, 259). Not only VCAM-1 expressed on 
endothelial cells, but also VCAM-1 on SMCs are suggested to influence atherosclerotic plaque 
formation (260). While the observed VCAM-1 expression could be a result of increased 
inflammatory burden, it could also be implicated in the formation of the atherosclerotic lesion. 
Trapping of macrophages in the vascular wall has been suggested to maintain a pro-
inflammatory environment and to inhibit cholesterol efflux from the vasculature, and the 
expression of VCAM-1 by SMCs is proposed to be one mechanism retaining macrophages in 
the plaque (261). 
IDO is a known regulator of T-cell function in vitro and in vivo. In Paper I, however, mostly 
innate immune cells such as macrophages, and vascular cells were affected by 1-MT treatment. 
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Staining of T cells in plaques, expression of T-cell markers in spleen and splenocyte 
proliferation rates were not affected by 1-MT treatment. As mice were sacrificed at the end of 
the experiment at 20 weeks of age after 8 weeks of treatment, it is possible that changes in the 
T-cell response were in effect earlier during the treatment. Changes in adaptive immune 
responses could modulate innate immune responses and lesion formation, thus having an 
impact on the results seen; however no certain effects on adaptive immunity could be seen in 
Paper I. 
Inhibition of IDO was achieved with the pharmacological inhibitor 1-MT. A mix of D and L 
isomers was used after initial pilot studies revealed the mix to be a more potent inhibitor of 
IDO in peripheral blood mononuclear cells (PBMCs) than the individual isomers. Effective 
systemic inhibition of IDO activity was confirmed by measuring the Kyn/Trp ratio in the spleen 
and duodenum. Although observations exist that would argue for specific roles of the different 
isomers where the L stereoisomer inhibits IDO1 (262) and only the D isomer inhibits IDO2 
(263), more recent work has cast doubt over this assumption (264). It is also known that 1-MT 
may have effects not related to its inhibition of IDO (265). Shortly after the publication of 
Paper I, Cole et al. published a study using IDO-/- ApoE-/- mice where deletion of IDO had a 
similar effect, i.e., aggravating plaque formation, as was observed in Paper I. This strengthens 
the hypothesis that the observed results were due to IDO inhibition. Furthermore, while not 
mechanistically proving the involvement of IDO, the observation that replenishment of the Kyn 
pathway by treatment with 3-HAA completely reversed the effect of 1-MT also supports the 
involvement of the Kyn pathway in the regulation of atherosclerosis. 
7.2 THE KYN METABOLITE 3-HAA ACTS BY INHIBITING SREBP-2 AND THE 
NLRP3 INFLAMMASOME  
We previously demonstrated the atheroprotective effect of the Kyn metabolite 3-HAA (231). 
However, the mechanisms by which 3-HAA reduces vascular inflammation and lowers plasma 
lipids were not known. In Paper II, we investigated the metabolic and immunological 
pathways affected by 3-HAA. In vitro systems using the human hepatoma cell line HepG2 
were set up to explore the metabolic effects of the metabolite, and mouse bone marrow-derived 
macrophages (BMDMs) were used to explore the mechanisms involved in innate immunity. 
Furthermore, a pharmacological inhibitor of the 3-HAA-degrading enzyme HAAO was used 
to explore the effects of endogenously produced 3-HAA in Ldlr-/- mice. 
When treated with 3-HAA, HepG2 cells exhibited a dose dependent reduction in SREBP-2 
transcription. Nuclear translocation of SREBP-2 (nSREBP-2) was also reduced. The 
expression of SREBP-1 was not affected; however, when stimulated with insulin, a known 
inducer of SREBP-1, treatment with 3-HAA also reduced SREBP-1 expression. Treatment 
with 3-HAA also reduced HepG2 secretion of ApoB-containing lipoproteins. Mouse BMDMs 
treated with 3-HAA showed a drastic inhibition of NLRP3 inflammasome activation, and the 
supernatant concentration of IL-1β was dose-dependently decreased. Curiously, the effect was 
present both when treatment with 3-HAA was carried out before LPS priming and when cells 
were treated only 30 minutes before activation with ATP. Investigation of cleaved caspase 1 
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by western blot showed a robust reduction in cleaved protein with 3-HAA treatment. To raise 
the level of endogenously produced 3-HAA, Ldlr-/- mice were treated with NCR-631, an 
HAAO inhibitor. Elevated endogenous 3-HAA levels resulted in reduced atherosclerosis in the 
aorta and lowered plasma lipids comparable to 3-HAA treatment. NCR-631 treatment did not 
affect plaque composition with regard to CD68+ macrophages or CD4+ T cells but did reduce 
aortic caspase 1, mainly uncleaved pro-caspase 1. In line with our in vitro results, NCR-631 
treatment reduced hepatic SREBP-2 and HMGCR expression, while SREBP-1 expression was 
unchanged. NCR-631 treatment reduced the lipid content in the liver, but did not affect LDL 
clearance from the plasma. 
SREBP-2 is a transcription factor that regulates cell sterol content, and increased activity 
corresponds to an increase in cell actions to acquire more sterols, both through synthesis and 
uptake. The increase in cholesterol uptake is utilized in statin treatment of 
hypercholesterolaemia, where inhibition of HMGCR induces the activation of SREBP-2 in 
hepatocytes, and the SREBP-2 induced upregulation of LDLR results in higher hepatic uptake 
of plasma lipoprotein particles (266). Treatment with 3-HAA also reduced the plasma 
lipoprotein content, but decreased SREBP-2 activity which suggests a different mode of action 
compared to statins. One plausible hypothesis is that 3-HAA reduces the synthesis of sterols 
by inhibiting SREBP-2. This hypothesis is supported by the observation that there was no 
increase in LDL clearance from plasma, while a lower cholesterol content was seen in the 
faeces of treated animals, although the observations were too few to draw robust conclusions. 
Furthermore, the reduced lipoprotein secretion in HepG2 cells could also be explained by 
reduced substrate synthesis. In Paper II, as in our earlier work with 3-HAA in Ldlr-/- mice 
(231), we see a clear effect on plasma lipids, while the effects of IDO inhibition on lipids in 
ApoE-/- mice in Paper I are only modest. Additionally, in models using genetic inhibition of 
IDO, mice with IDO-/- on an Ldlr-/- background displayed an increase in plasma lipids, mainly 
TAG (230), while IDO-/- on an ApoE-/- background was not reported to show major changes in 
plasma lipids (242). LDLR is a direct target regulated by SREBP-2, and it is possible that if the 
lipid-lowering effect of 3-HAA is mediated by SREBP-2 inhibition, a parallel inhibition of 
Ldlr transcription would counteract the lipid-lowering effect in ApoE-/- mice. 
The regulation of SREBP-2 activity is active on several levels. As SREBP-2 transcription is 
partly regulated by a feed-forward mechanism (267), decreased nuclear translocation may 
further decrease the transcription of new SREBP-2. Interestingly, we found a similar effect on 
SREBP-2 expression in HepG2 cells when treated with a PDPK1 inhibitor as when treated with 
3-HAA. One suggested target of 3-HAA is PDPK1 (115). The PDPK1 – AKT – mTOR 
pathway is also implicated in SREBP regulation, where activation of the pathway stimulates 
SREBP activation (268). Intriguingly, the NLRP3 inflammasome has also been proposed to be 
regulated by the AKT – mTOR pathway, possibly linking our findings of 3-HAA action on 
both SREBP-2 and NLRP3 inflammasome (269). Alternatively, SREBP-2 is suggested to have 
a direct effect on NLRP3 activity (254).The finding that 3-HAA inhibited inflammasomes both 
when treatment was given during priming, but also shortly before assembly induced by ATP 
would suggest, at least in part, a direct effect of 3-HAA on assembly of the inflammasome, as 
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there would be insufficient time for effects mediated by gene transcription. The inhibitor  
NCR-631 increases the endogenous levels of 3-HAA (270). As a decrease was seen in pro-
caspase 1 expression in the aortas of NCR-631 treated mice, it is possible that 3-HAA affects 
both the priming and assembly of the inflammasome. 
7.3 DEVIATION OF THE KYN PATHWAY AWAY FROM KYNA FORMATION 
AGGRAVATES HUMAN ATHEROSCLEROSIS 
The role of the Kyn pathway and the balance of different branches within the pathway, in 
human atherosclerosis were explored in Paper III. Transcriptomic data from human 
atherosclerotic plaques available through a collaboration with the BiKE biobank were analysed 
for the expression of Kyn pathway enzymes. We found that the first common steps of the 
pathway, and the branch of the pathway leading to the formation of QA (the “QA branch”) 
were upregulated in atherosclerotic plaques compared to healthy arteries, while the branch of 
the pathway leading to KynA (the “KynA branch”) was downregulated. Correlations were 
made between the expression of Kyn pathway enzymes and the expression of pro- and anti-
inflammatory genes. The main enzymes of the QA branch were found to have a positive 
correlation with pro-inflammatory and plaque-destabilizing genes, whereas enzymes of the 
KynA branch were found to have an inverse correlation with such genes and instead correlated 
with the expression of stabilizing and tolerogenic factors. Sections of plaque material were 
stained for the expression of Kyn pathway enzymes, and while a clear upregulation in sites of 
macrophage activity near the necrotic core could be seen for IDO and KMO from the common 
and QA branch of the pathway, respectively, KYAT1 from the KynA branch did not have the 
same staining pattern. Expression patterns of plaques from symptomatic and asymptomatic 
patients were compared, both at the mRNA and protein levels, and plasma was analysed for 
Kyn pathway metabolites. Symptomatic plaques showed a decrease in the expression of KYAT 
enzymes, both in mRNA and protein. Enzyme activity of the KynA branch was decreased in 
symptomatic patients, as seen by the lower KynA/3-HAA ratio. Interestingly, activity of the 
common branch, which includes IDO, was also lower in symptomatic patients as seen by the 
lower Kyn/Trp ratio. 
Clinical parameters were retrieved, and a logistic regression model was set up to describe the 
effect of KYAT expression on the odds of being symptomatic or asymptomatic. A significant 
decrease in the odds of having presented with symptoms was seen with increasing expression 
of KYAT1. The molecular mechanism by which the Kyn pathway metabolite KynA acts was 
further explored in vitro. Treatment of macrophages generated from human PBMCs indicated 
that KynA has anti-inflammatory properties that are mediated via activation of the AhR. The 
anti-inflammatory properties of KynA were confirmed in a mouse model of peritonitis. 
Activation of the Kyn pathway has previously been described in CVD in epidemiological 
studies (233-237). The expression of IDO has been shown in advanced atherosclerotic plaques 
(271). However, Paper III explores the specific intermediate steps of the Kyn pathway in 
atherosclerosis and how changes within the pathway affect the atherosclerotic plaque. One 
advantage of using material from the BiKE biobank is that when comparing symptomatic and 
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asymptomatic plaques, both groups have advanced disease that requires surgery. When 
studying the Kyn pathway, which is strongly upregulated by inflammation, there is always a 
question of whether observed differences between groups could be the result of underlying 
differences in inflammation. By comparing two groups that both have advanced disease, such 
as symptomatic and asymptomatic patients in BiKE, this problem could be partially mitigated. 
It is therefore interesting that we observed increased IDO activity, demonstrated by an 
increased Kyn/Trp ratio, in plasma from asymptomatic patients. This observation goes well 
with the finding of a recent Mendelian randomization study that found genetically instrumented 
IDO activity to be protective in ischaemic heart disease (241). 
In Paper III, we demonstrate that a deviation from the KynA branch of the Kyn pathway, to 
the QA branch of the pathway, is associated with a more inflammatory plaque phenotype and 
higher odds of being a symptomatic patient. In Paper I and Paper II, and in earlier work (231), 
we demonstrated that 3-HAA, a metabolite within the QA branch of the Kyn pathway, is 
atheroprotective. As we did not evaluate all individual metabolites in Paper III, the properties 
of the particular metabolite 3-HAA could still be atheroprotective. Furthermore, the common 
branch of the Kyn pathway is upregulated in both asymptomatic and symptomatic patients. In 
Paper I and Paper II, we did not study how 3-HAA treatment affected the Kyn pathway, and 
it is possible that administration of a QA branch metabolite also changed the flux in the KynA 
branch of the pathway. In the study by Zhang et al. (231), however, we showed that 3-HAA 
treatment downregulated hepatic KYNU and HAAO expression, suggesting a possible role of 
3-HAA in modulating Kyn pathway flux. 
In immunohistochemistry stainings, we show that IDO and KMO are most upregulated in areas 
of plaques rich in macrophages and immune cells. This raises the question of in which cells of 
the atherosclerotic plaque does the observed deviation of the Kyn pathway take place. Using 
transcriptomic data from PBMCs from BiKE patients, we observed a weak trend towards a 
similar deviation of the Kyn pathway away from KynA formation in PBMCs from 
symptomatic patients, as was seen in plaque tissue (Figure 4).  
 
Figure 4: Expression of KYAT1 in PBMCs from BiKE. A trend towards decreased 
expression is seen. AS; asymptomatic. S; symptomatic. # p<0.1 
 
 
To further investigate the deviation of the Kyn pathway in circulating myeloid cells, a publicly 
available data set, consisting of transcriptomic data from CD14+ cells from a population study, 
with measurement of the coronary artery calcium (CAC) score (available through NCBI-GEO, 
http://www.ncbi.nlm.nih.gov/geo, GSE56045, deposited by Yongmei Liu, previously 
published (272)) was used. Subjects were stratified based on CAC-score as previously shown 
(273). In subjects with above median expression of KYAT1, there was a clearly reduced odds 
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ratio of having the highest category of CAC-score compared to subjects with below median 
KYAT1 expression (Table 2). However, the same pattern was not observed with KYAT2 (data 
not shown). These findings raise the question of whether deviation of the Kyn pathway is 
already present in circulating immune cells, in addition to locally in the atherosclerotic plaque, 
something that warrants future studies. 
Table 2: High or low KYAT1 expression in a population study. “Median Low” denotes KYAT1 expression below 
the median, “Median High” denotes KYAT1 expression above the median. OR refers to the odds of a patient 
having the specified CAC-score comparing above the median expression level to below the median expression 
level.* p<0.05. 
 No CAC Low CAC Intermediate CAC High CAC Total Missing 
Total 337 324 187 293 1141 61 
Median Low 166 163 87 171 587  
Median High 171 161 100 122 554  
OR (CI95%) 
1,132 
(0,878-1,460) 
1,066 
(0,824-1,378) 
1,266 
(0,925-1,733) 
0,687 
(0,525-0,899) 
  
χ2-test 0,338 0,628 0,141 0,006*   
 
7.4 METABOLIC REPROGRAMMING VIA PDK1 INHIBITION REGULATES 
VASCULAR INFLAMMATION 
In Paper IV, we explored the role of metabolic reprogramming by targeting PDKs with the 
inhibitor DCA in atherosclerosis. We show that treatment of ApoE-/- mice on a western-type 
diet with DCA drastically reduces atherosclerotic burden. Furthermore, treatment with DCA 
reduced plaque inflammation, as demonstrated by a reduction in infiltrating CD68+ 
macrophages and CD4+ T cells while increasing plaque stability by increasing alpha smooth 
muscle actin and collagen in the plaque. A distinct change in immunological phenotype was 
observed upon DCA treatment, with a reduction in M1-like macrophage markers, upregulation 
of M2-like macrophage markers and downregulation of markers of TH1-type responses in both 
spleen and aorta. Interestingly, we demonstrate that DCA has the ability to block NLRP3 
inflammasome activation and IL-1β secretion from macrophages.  
Metabolomic studies revealed, apart from an expected shift away from lactate production, that 
DCA treatment reduces cell accumulation of succinate. The addition of succinate abrogated the 
effects of DCA on NLRP3 inhibition. The reversal of the DCA effect on NLRP3 
inflammasome by succinate was not seen when treated with a GPR91 antagonist, implicating 
the succinate receptor GPR91 signalling as a potential mechanism of succinate to increase 
inflammasome activity. Furthermore, we showed that DCA treatment decreased the expression 
of PDK in the spleen and aorta, in the latter particularly isoforms PDK1 and PDK4, but not in 
liver. In human carotid artery tissue, PDK1 protein expression was increased in plaque 
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compared to adjacent tissue, and DCA had a reducing effect on the secretion of pro-
inflammatory cytokines by plaque cells cultured in vitro.  
Similar to our study, a recently published study also found that DCA reduces the atherosclerotic 
burden in ApoE-/- mice (274). DCA was found to reduce white adipose tissue and induce 
thermogenesis and increase the expression of the brown adipose tissue marker uncoupling 
protein 1. The study suggested that the effect of DCA was at least partly mediated by hepatic 
expression of fibroblast growth factor 21. Additionally, in our study we observed changes not 
only in glucose metabolism but also in lipid metabolism, with a decrease in plasma cholesterol 
at the end of the study. The observed metabolic changes in lipid metabolism, both in the study 
of Min et al. (274) and in our study, are surprising considering that the activity of PDK has 
been argued to promote lipolysis (121). The observed ability of DCA to promote glucose 
oxidation without apparent accumulation of lipids warrants further investigation. 
The connection between aberrant immune activation and increased lactate production is 
clinically well recognized, particularly in sepsis and septic shock. While there have been 
clinical trials of DCA treatment in septic patients, the most complete studies failed to show an 
effect on mortality and haemodynamic function (275). It is worth noting however, that the 
study of Stacpoole et al. included not only septic patients but all patients with severe lactic 
acidosis and that the inclusion criteria favoured the recruitment of patients with advanced 
disease and a poor prognosis. Experimental data argue for the ability of DCA to reprogram the 
immune response, inhibiting the maladaptive immune response in sepsis and improving the 
survival of mice undergoing caecal ligation and puncture, an experimental sepsis model (276). 
The reprogramming of the immune system observed in Paper IV could thus be applied in 
several other clinical settings beyond atherosclerosis. 
7.5 CONCLUDING REMARKS 
The idea that atherosclerosis is a chronic inflammatory disease is widely accepted today. Yet, 
no therapies routinely used in the clinical setting specifically target the underlying 
inflammatory responses driving atherosclerosis. The close link between metabolism and the 
immune response offers a new approach to investigate important mechanisms in the 
pathophysiology of atherosclerosis, and to discover new and better avenues for treatment.  
Paper I, II and III of this thesis focus on the strong immune regulatory potential of Trp 
metabolism through the Kyn pathway. Inhibition of Trp metabolism results in increased 
inflammation and atherosclerosis. The Trp metabolite 3-HAA is shown to regulate sterol 
metabolism by inhibiting SREBP2 activity, and a deviation away from KynA production is 
seen in symptomatic carotid atherosclerosis.  
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In Paper IV the PDK inhibitor DCA was investigated in the context of atherosclerosis. Active 
immune cells, both T cells and macrophages, favours aerobic glycolysis and lactate production 
over TCA cycle, and treatment with DCA reduced atherosclerotic burden in mice. A summary 
of the findings in this thesis can be seen in Figure 5. 
The field of immunometabolism, the study of the interplay between the traditional science 
disciplines of metabolism and immunology, is an emerging field of research. The present thesis 
highlights the potent immune-modulating potential that can be achieved from manipulation of 
one metabolic pathway, the Kyn pathway of Trp metabolism. The Kyn pathway has several 
features that makes it promising as a therapeutic target. The metabolites in the pathway are 
small molecules and as such more convenient as analogues for pharmacological agents than, 
for example, large proteins such as antibodies which are complicated to produce and to 
administer. For several enzymes in the Kyn pathway there are well-established 
pharmacological inhibitors that already are used in vivo, as seen in Paper I and II. The use of 
1-MT in cancer therapy will hopefully add knowledge of the clinical implication of Kyn 
pathway modulation over the coming years. The present thesis highlights the need for careful 
cardiovascular surveillance in patients receiving IDO inhibitors. Furthermore, several 
metabolites of the Kyn pathway are quickly degraded and have short half-lives in plasma, 
which necessitates further research before they can effectively be used as pharmacological 
agents. 
The reprogramming of the immune response in atherosclerosis after modulation of glucose 
metabolism with DCA observed in Paper IV can be generalized to several other settings 
outside of the field of CVD. Regulation of glucose metabolism, succinate availability and TCA 
flux is of interest in any inflammatory response. It is the hope and belief of the author that the 
insights gained from the studies in the present thesis, together with other work in the field of 
immunometabolism, will provide new approaches to treatment and prevention of not only 
atherosclerosis, but all inflammatory diseases. 
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Figure 5. A summary of findings in the current thesis. Modulation of metabolism of tryptophan or metabolic 
flow through the glycolytic pathway is associated with the level of inflammation, and can be observed both in 
liver, arteries and at the level of immune cells. 3-HAA, 3-hydroxyanthranilic acid; DCA, dichloroacetate; TCA, 
citric acid cycle; SREBP2, sterol response element binding protein 2; IL, interleukin. 
  
  49 
8 ACKNOWLEDGEMENTS 
During my years as a PhD-student I have received enormous support from so many intelligent 
and co-workers and friends. I would in particular like to thank: 
My main supervisor, Daniel Ketelhuth for taking me in and guiding me on my scientific path 
all these years. Your warm and kind personality together with your knowledge and skill as a 
researcher make for a wonderful supervisor and I feel very privileged to have had the 
opportunity to learn from you.  
My co-supervisor Göran Hansson who made my recruitment to the lab possible and who has 
shared so much good advice in the making of this thesis. Without your expertise in the field, 
this thesis would not have been possible. 
My co-supervisor Alice Assinger. While time was not enough for some of the studies we had 
planned, you always supported me and made sure to give me some kind words when you were 
in Stockholm. 
All past and present members of the Ketelhuth team; Konstantinos Polyzos, Maria-José 
Forteza, Roland Baumgartner, Ilona Kareinen, Aastha Arora, Gustavo Tripodi and 
Felipe Beccaria Casagrande. Thank you for all the hours of hard work we shared 
collaborating in the lab, and thank you for the wonderful time we have shared outside the lab, 
the beers, showing me your hometowns and discussing life’s big questions in between the 
science. I am glad to have friends such as you. 
My mentor Sigrid Lundberg, for your long term commitment to me, for always being a 
support to count on in both good and bad times. 
A very warm thank you to Anneli Olsson, Linda Haglund and Ingrid Törnberg. Without 
your technical skills the studies in this thesis would not have been made. In addition to being 
excellent professionals, you made me feel at home in the lab and were always a joy to be 
around. 
Thanks Gabrielle Paulsson-Berne for always looking out for the rest of us, and occasionally 
giving me a nudge in the right direction, and all other principal investigators, Magnus Bäck, 
Zhong-Qun Yan, Peder Olofsson and Stephen Malin for the fruitful discussions over the 
years. 
I would like to thank all my fellow PhD-students, Glykeria Karadimou, Miguel Carracedo, 
Gonzalo Artiach Castañon, Marcelo Petri, Nikolaos Skenteris, Xintong Jiang, Xiao-Ying 
Zhang, Yajuan Wang, April Caravaca, Alessandro Gallina, Monica Centa, Katrin Habir, 
Tinna Christersdottir, Daniela Strodthoff, Bianca Suur, Samuel Röhl, for all the laughs 
and good times we have shared. You are inspiring persons and I hope to continue sharing both 
science and laughs with you over the coming years. A special thanks to Leif Söderström for 
bringing me in to the lab. 
 50 
To all the postdoctoral fellows, Anton Gisterå, Silke Thul, Andrés Laguna Fernandéz, Silke 
Thul, Hildur Arnardottir, John Pirault, Reiner Mailer, Sanna Hellberg, Laura 
Tarnawski, Daniel Johansson, Hanna Agardh, Vladimir Shavva, Sven Pawelzik, Lasse 
Folkersen, Olga Ovchinnikova, Maria Klement, Albert Dahdah and Kajsa Prokopec, who 
have guided me both amid the pipettes and outside of the lab. 
Thanks also to Selam Assefa for excellent help at AKM. 
For much-appreciated guidance and collaboration, particularly towards the end of my studies, 
I would like to thank Per Eriksson. Thank you also Ulf Hedin and Ljubica Matic for good 
collaborations. 
Thanks to all my friends, particularly KB for technical support with making figures and also 
for supporting me in preparing a dinner together with David Stigson. 
Finally, I would like to thank my family, my parents Sören and Katarina, and my brother 
Henrik for all their support and input, and my partner Sebastian for invaluable support and 
encouragement. 
 
  51 
9 REFERENCES 
 
1. Global Health Estimates 2016: Deaths by Cause, Age, Sex, by Country and by 
Region, 2000-2016. Geneva: World Health Organization; 2018. 
2. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng 
S, et al. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart 
Association. Circulation. 2018;137(12):e67-e492. 
3. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N 
Engl J Med. 2005;352(16):1685-95. 
4. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J, 3rd. Factors of risk 
in the development of coronary heart disease--six year follow-up experience. The 
Framingham Study. Ann Intern Med. 1961;55:33-50. 
5. Pencina MJ, D'Agostino RB, Sr., Larson MG, Massaro JM, Vasan RS. 
Predicting the 30-year risk of cardiovascular disease: the framingham heart study. 
Circulation. 2009;119(24):3078-84. 
6. Carlsson AC, Wandell PE, de Faire U, Hellenius ML. Prevalence of 
hypertension in immigrants and Swedish-born individuals, a cross-sectional study of 60-year-
old men and women in Sweden. J Hypertens. 2008;26(12):2295-302. 
7. Carroll MD, Fryar CD, Nguyen DT. Total and High-density Lipoprotein 
Cholesterol in Adults: United States, 2015–2016. NCHS data brief. 2017(290). 
8. Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, et al. Effect of 
potentially modifiable risk factors associated with myocardial infarction in 52 countries (the 
INTERHEART study): case-control study. The Lancet. 2004;364(9438):937-52. 
9. Robinson JG, Huijgen R, Ray K, Persons J, Kastelein JJ, Pencina MJ. 
Determining When to Add Nonstatin Therapy: A Quantitative Approach. J Am Coll Cardiol. 
2016;68(22):2412-21. 
10. Mayerl C, Lukasser M, Sedivy R, Niederegger H, Seiler R, Wick G. 
Atherosclerosis research from past to present--on the track of two pathologists with opposing 
views, Carl von Rokitansky and Rudolf Virchow. Virchows Arch. 2006;449(1):96-103. 
11. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et 
al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable 
angina. N Engl J Med. 1994;331(7):417-24. 
12. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. 
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N 
Engl J Med. 1997;336(14):973-9. 
13. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. 
Nature. 1993;362(6423):801-9. 
14. Crowson CS, Liao KP, Davis JM, 3rd, Solomon DH, Matteson EL, Knutson 
KL, et al. Rheumatoid arthritis and cardiovascular disease. Am Heart J. 2013;166(4):622-8 
e1. 
15. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, 
et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J 
Med. 2017;377(12):1119-31. 
 52 
16. Tang D, Kang R, Coyne CB, Zeh HJ, Lotze MT. PAMPs and DAMPs: signal 
0s that spur autophagy and immunity. Immunol Rev. 2012;249(1):158-75. 
17. Beutler BA. TLRs and innate immunity. Blood. 2009;113(7):1399-407. 
18. Ullah MO, Sweet MJ, Mansell A, Kellie S, Kobe B. TRIF-dependent TLR 
signaling, its functions in host defense and inflammation, and its potential as a therapeutic 
target. J Leukoc Biol. 2016;100(1):27-45. 
19. Ting JP, Lovering RC, Alnemri ES, Bertin J, Boss JM, Davis BK, et al. The 
NLR gene family: a standard nomenclature. Immunity. 2008;28(3):285-7. 
20. Kim YK, Shin JS, Nahm MH. NOD-Like Receptors in Infection, Immunity, 
and Diseases. Yonsei Med J. 2016;57(1):5-14. 
21. Schroder K, Tschopp J. The inflammasomes. Cell. 2010;140(6):821-32. 
22. Kapellos TS, Bonaguro L, Gemund I, Reusch N, Saglam A, Hinkley ER, et al. 
Human Monocyte Subsets and Phenotypes in Major Chronic Inflammatory Diseases. Front 
Immunol. 2019;10:2035. 
23. Geissmann F, Jung S, Littman DR. Blood Monocytes Consist of Two Principal 
Subsets with Distinct Migratory Properties. Immunity. 2003;19(1):71-82. 
24. Ginhoux F, Guilliams M. Tissue-Resident Macrophage Ontogeny and 
Homeostasis. Immunity. 2016;44(3):439-49. 
25. Orecchioni M, Ghosheh Y, Pramod AB, Ley K. Macrophage Polarization: 
Different Gene Signatures in M1(LPS+) vs. Classically and M2(LPS-) vs. Alternatively 
Activated Macrophages. Front Immunol. 2019;10:1084. 
26. Awad F, Assrawi E, Jumeau C, Georgin-Lavialle S, Cobret L, Duquesnoy P, et 
al. Impact of human monocyte and macrophage polarization on NLR expression and NLRP3 
inflammasome activation. PLoS One. 2017;12(4):e0175336. 
27. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage 
subsets. Nat Rev Immunol. 2011;11(11):723-37. 
28. Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of 
the human monocyte-to-macrophage differentiation and polarization: new molecules and 
patterns of gene expression. J Immunol. 2006;177(10):7303-11. 
29. Collin M, Bigley V. Human dendritic cell subsets: an update. Immunology. 
2018;154(1):3-20. 
30. Steinman RM. Decisions about dendritic cells: past, present, and future. Annu 
Rev Immunol. 2012;30:1-22. 
31. Reizis B. Plasmacytoid Dendritic Cells: Development, Regulation, and 
Function. Immunity. 2019;50(1):37-50. 
32. Karolinska Universitetslaboratoriet Stockholm, Sweden [updated 2018-01-
19Cited 2020-01-16]. Available from: https://www.karolinska.se/for-vardgivare/karolinska-
universitetslaboratoriet/. 
33. Liew PX, Kubes P. The Neutrophil's Role During Health and Disease. Physiol 
Rev. 2019;99(2):1223-48. 
34. Kovanen PT, Bot I. Mast cells in atherosclerotic cardiovascular disease - 
Activators and actions. Eur J Pharmacol. 2017;816:37-46. 
  53 
35. Sarma JV, Ward PA. The complement system. Cell Tissue Res. 
2011;343(1):227-35. 
36. Abbas AK, Lichtman AH, Pillai S. Basic Immunology: Functions and 
Disorders of the Immune System. Philadelphia, PA: Saunders; 2012. 
37. Zarnitsyna VI, Evavold BD, Schoettle LN, Blattman JN, Antia R. Estimating 
the diversity, completeness, and cross-reactivity of the T cell repertoire. Front Immunol. 
2013;4:485. 
38. Murphy KM, Reiner SL. The lineage decisions of helper T cells. Nat Rev 
Immunol. 2002;2(12):933-44. 
39. Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, 
et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature. 
2006;441(7090):231-4. 
40. Raffin C, Vo LT, Bluestone JA. Treg cell-based therapies: challenges and 
perspectives. Nat Rev Immunol. 2019. 
41. van Puijvelde GHM, Kuiper J. NKT cells in cardiovascular diseases. Eur J 
Pharmacol. 2017;816:47-57. 
42. Nutt SL, Hodgkin PD, Tarlinton DM, Corcoran LM. The generation of 
antibody-secreting plasma cells. Nat Rev Immunol. 2015;15(3):160-71. 
43. Baumgarth N. A Hard(y) Look at B-1 Cell Development and Function. J 
Immunol. 2017;199(10):3387-94. 
44. Sage AP, Tsiantoulas D, Binder CJ, Mallat Z. The role of B cells in 
atherosclerosis. Nat Rev Cardiol. 2019;16(3):180-96. 
45. Margo CE, Harman LE. Autoimmune disease: Conceptual history and 
contributions of ocular immunology. Surv Ophthalmol. 2016;61(5):680-8. 
46. Svensson M, Maroof A, Ato M, Kaye PM. Stromal cells direct local 
differentiation of regulatory dendritic cells. Immunity. 2004;21(6):805-16. 
47. Wakkach A, Fournier N, Brun V, Breittmayer J-P, Cottrez F, Groux H. 
Characterization of Dendritic Cells that Induce Tolerance and T Regulatory 1 Cell 
Differentiation In Vivo. Immunity. 2003;18(5):605-17. 
48. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of 
the immune system. Nat Rev Immunol. 2009;9(3):162-74. 
49. Forrester JV, Xu H, Lambe T, Cornall R. Immune privilege or privileged 
immunity? Mucosal Immunol. 2008;1(5):372-81. 
50. Tellides G, Pober JS. Inflammatory and immune responses in the arterial 
media. Circ Res. 2015;116(2):312-22. 
51. Rang HP, Dale MM, Ritter JM, Flower RJ. Pharmacology. Philadelphia: 
Churchill Livingstone; 2007. 
52. Serhan CN, Savill J. Resolution of inflammation: the beginning programs the 
end. Nat Immunol. 2005;6(12):1191-7. 
53. Back M, Yurdagul A, Jr., Tabas I, Oorni K, Kovanen PT. Inflammation and its 
resolution in atherosclerosis: mediators and therapeutic opportunities. Nat Rev Cardiol. 
2019;16(7):389-406. 
 54 
54. Gray-Donald K, Jacobs-Starkey L, Johnson-Down L. Food habits of 
Canadians: reduction in fat intake over a generation. Can J Public Health. 2000;91(5):381-5. 
55. Nordic Nutrition Recommendations 2012. Copenhagen: Nordisk Ministerråd; 
2014. 
56. Gimeno RE, Hirsch DJ, Punreddy S, Sun Y, Ortegon AM, Wu H, et al. 
Targeted deletion of fatty acid transport protein-4 results in early embryonic lethality. J Biol 
Chem. 2003;278(49):49512-6. 
57. Abumrad N, Harmon C, Ibrahimi A. Membrane transport of long-chain fatty 
acids: evidence for a facilitated process. J Lipid Res. 1998;39(12):2309-18. 
58. Wang TY, Liu M, Portincasa P, Wang DQ. New insights into the molecular 
mechanism of intestinal fatty acid absorption. Eur J Clin Invest. 2013;43(11):1203-23. 
59. Altmann SW, Davis HR, Jr., Zhu LJ, Yao X, Hoos LM, Tetzloff G, et al. 
Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science. 
2004;303(5661):1201-4. 
60. Berg JM, Tymoczko JL, Gatto Jr. GJ, Stryer L. Biochemistry. New York: 
Macmillan International; 2019. 
61. Dash S, Xiao C, Morgantini C, Lewis GF. New Insights into the Regulation of 
Chylomicron Production. Annu Rev Nutr. 2015;35:265-94. 
62. Davies BS, Beigneux AP, Barnes RH, 2nd, Tu Y, Gin P, Weinstein MM, et al. 
GPIHBP1 is responsible for the entry of lipoprotein lipase into capillaries. Cell Metab. 
2010;12(1):42-52. 
63. Kersten S. Physiological regulation of lipoprotein lipase. Biochim Biophys 
Acta. 2014;1841(7):919-33. 
64. Tiwari S, Siddiqi SA. Intracellular trafficking and secretion of VLDL. 
Arterioscler Thromb Vasc Biol. 2012;32(5):1079-86. 
65. Mendivil CO, Rimm EB, Furtado J, Sacks FM. Apolipoprotein E in VLDL and 
LDL with apolipoprotein C-III is associated with a lower risk of coronary heart disease. J Am 
Heart Assoc. 2013;2(3):e000130. 
66. Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor 
gene in familial hypercholesterolemia. Hum Mutat. 1992;1(6):445-66. 
67. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, et al. 
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 
2003;34(2):154-6. 
68. Park SW, Moon YA, Horton JD. Post-transcriptional regulation of low density 
lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J 
Biol Chem. 2004;279(48):50630-8. 
69. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and 
reverse cholesterol transport. Circ Res. 2005;96(12):1221-32. 
70. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et 
al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 
2007;357(21):2109-22. 
  55 
71. Shao W, Espenshade PJ. Expanding roles for SREBP in metabolism. Cell 
Metab. 2012;16(4):414-9. 
72. Shimano H, Horton JD, Shimomura I, Hammer RE, Brown MS, Goldstein JL. 
Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers 
of transgenic mice and in cultured cells. J Clin Invest. 1997;99(5):846-54. 
73. Oberkofler H, Schraml E, Krempler F, Patsch W. Restoration of sterol-
regulatory-element-binding protein-1c gene expression in HepG2 cells by peroxisome-
proliferator-activated receptor-gamma co-activator-1alpha. Biochem J. 2004;381(Pt 2):357-
63. 
74. Goldstein JL, DeBose-Boyd RA, Brown MS. Protein sensors for membrane 
sterols. Cell. 2006;124(1):35-46. 
75. Espenshade PJ, Cheng D, Goldstein JL, Brown MS. Autocatalytic processing 
of site-1 protease removes propeptide and permits cleavage of sterol regulatory element-
binding proteins. J Biol Chem. 1999;274(32):22795-804. 
76. Temel RE, Tang W, Ma Y, Rudel LL, Willingham MC, Ioannou YA, et al. 
Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of 
ezetimibe. J Clin Invest. 2007;117(7):1968-78. 
77. Moffett JR, Namboodiri MA. Tryptophan and the immune response. Immunol 
Cell Biol. 2003;81(4):247-65. 
78. Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, 
et al. Proteomics. Tissue-based map of the human proteome. Science. 
2015;347(6220):1260419. 
79. TDO2 Stockholm: The Human Protein Atlas;  [Available from: 
http://www.proteinatlas.org. 
80. Salter M, Knowles RG, Pogson CI. Quantification of the importance of 
individual steps in the control of aromatic amino acid metabolism. Biochem J. 
1986;234(3):635-47. 
81. Badawy AA. Kynurenine Pathway of Tryptophan Metabolism: Regulatory and 
Functional Aspects. Int J Tryptophan Res. 2017;10:1178646917691938. 
82. Badawy AA, Evans M. Animal liver tryptophan pyrrolases: Absence of 
apoenzyme and of hormonal induction mechanism from species sensitive to tryptophan 
toxicity. Biochem J. 1976;158(1):79-88. 
83. Too LK, Li KM, Suarna C, Maghzal GJ, Stocker R, McGregor IS, et al. 
Deletion of TDO2, IDO-1 and IDO-2 differentially affects mouse behavior and cognitive 
function. Behav Brain Res. 2016;312:102-17. 
84. Yamamoto S, Hayaishi O. Tryptophan pyrrolase of rabbit intestine. D- and L-
tryptophan-cleaving enzyme or enzymes. J Biol Chem. 1967;242(22):5260-6. 
85. Hayaishi O. My life with tryptophan--never a dull moment. Protein Sci. 
1993;2(3):472-5. 
86. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, et al. 
Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. 
1998;281(5380):1191-3. 
 56 
87. Munn DH, Sharma MD, Lee JR, Jhaver KG, Johnson TS, Keskin DB, et al. 
Potential regulatory function of human dendritic cells expressing indoleamine 2,3-
dioxygenase. Science. 2002;297(5588):1867-70. 
88. Hwu P, Du MX, Lapointe R, Do M, Taylor MW, Young HA. Indoleamine 2,3-
Dioxygenase Production by Human Dendritic Cells Results in the Inhibition of T Cell 
Proliferation. The Journal of Immunology. 2000;164(7):3596-9. 
89. Fallarino F, Grohmann U, Hwang KW, Orabona C, Vacca C, Bianchi R, et al. 
Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol. 2003;4(12):1206-
12. 
90. Wek SA, Zhu S, Wek RC. The histidyl-tRNA synthetase-related sequence in 
the eIF-2 alpha protein kinase GCN2 interacts with tRNA and is required for activation in 
response to starvation for different amino acids. Mol Cell Biol. 1995;15(8):4497-506. 
91. Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D, et al. GCN2 
kinase in T cells mediates proliferative arrest and anergy induction in response to 
indoleamine 2,3-dioxygenase. Immunity. 2005;22(5):633-42. 
92. Liu H, Huang L, Bradley J, Liu K, Bardhan K, Ron D, et al. GCN2-dependent 
metabolic stress is essential for endotoxemic cytokine induction and pathology. Mol Cell 
Biol. 2014;34(3):428-38. 
93. Metz R, Rust S, Duhadaway JB, Mautino MR, Munn DH, Vahanian NN, et al. 
IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector 
pathway targeted by D-1-methyl-tryptophan. Oncoimmunology. 2012;1(9):1460-8. 
94. Yan Y, Zhang GX, Gran B, Fallarino F, Yu S, Li H, et al. IDO upregulates 
regulatory T cells via tryptophan catabolite and suppresses encephalitogenic T cell responses 
in experimental autoimmune encephalomyelitis. J Immunol. 2010;185(10):5953-61. 
95. Gurtner GJ, Newberry RD, Schloemann SR, McDonald KG, Stenson WF. 
Inhibition of indoleamine 2,3-dioxygenase augments trinitrobenzene sulfonic acid colitis in 
mice. Gastroenterology. 2003;125(6):1762-73. 
96. Szanto S, Koreny T, Mikecz K, Glant TT, Szekanecz Z, Varga J. Inhibition of 
indoleamine 2,3-dioxygenase-mediated tryptophan catabolism accelerates collagen-induced 
arthritis in mice. Arthritis Res Ther. 2007;9(3):R50. 
97. Hou W, Huang G, Cao X, Zhang Y, Zhang J, Li Y. Suppression of 
experimental autoimmune glomerulonephritis by tryptophan. J Nephrol. 2014;27(1):19-28. 
98. Chaudhary K, Shinde R, Liu H, Gnana-Prakasam JP, Veeranan-Karmegam R, 
Huang L, et al. Amino acid metabolism inhibits antibody-driven kidney injury by inducing 
autophagy. J Immunol. 2015;194(12):5713-24. 
99. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, et al. 
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by 
indoleamine 2,3-dioxygenase. Nat Med. 2003;9(10):1269-74. 
100. Fox E, Oliver T, Rowe M, Thomas S, Zakharia Y, Gilman PB, et al. 
Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer. Front 
Oncol. 2018;8:370. 
101. DiNatale BC, Murray IA, Schroeder JC, Flaveny CA, Lahoti TS, Laurenzana 
EM, et al. Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that 
  57 
synergistically induces interleukin-6 in the presence of inflammatory signaling. Toxicol Sci. 
2010;115(1):89-97. 
102. Wang J, Simonavicius N, Wu X, Swaminath G, Reagan J, Tian H, et al. 
Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem. 
2006;281(31):22021-8. 
103. Stockinger B, Di Meglio P, Gialitakis M, Duarte JH. The aryl hydrocarbon 
receptor: multitasking in the immune system. Annu Rev Immunol. 2014;32:403-32. 
104. Kimura A, Naka T, Nakahama T, Chinen I, Masuda K, Nohara K, et al. Aryl 
hydrocarbon receptor in combination with Stat1 regulates LPS-induced inflammatory 
responses. J Exp Med. 2009;206(9):2027-35. 
105. Malaczewska J, Siwicki AK, Wojcik RM, Turski WA, Kaczorek E. The effect 
of kynurenic acid on the synthesis of selected cytokines by murine splenocytes - in vitro and 
ex vivo studies. Cent Eur J Immunol. 2016;41(1):39-46. 
106. Maaetoft-Udsen K, Shimoda LM, Frokiaer H, Turner H. Aryl hydrocarbon 
receptor ligand effects in RBL2H3 cells. J Immunotoxicol. 2012;9(3):327-37. 
107. Barth MC, Ahluwalia N, Anderson TJ, Hardy GJ, Sinha S, Alvarez-Cardona 
JA, et al. Kynurenic acid triggers firm arrest of leukocytes to vascular endothelium under 
flow conditions. J Biol Chem. 2009;284(29):19189-95. 
108. Kiank C, Zeden JP, Drude S, Domanska G, Fusch G, Otten W, et al. 
Psychological stress-induced, IDO1-dependent tryptophan catabolism: implications on 
immunosuppression in mice and humans. PLoS One. 2010;5(7):e11825. 
109. Tiszlavicz Z, Nemeth B, Fulop F, Vecsei L, Tapai K, Ocsovszky I, et al. 
Different inhibitory effects of kynurenic acid and a novel kynurenic acid analogue on tumour 
necrosis factor-alpha (TNF-alpha) production by mononuclear cells, HMGB1 production by 
monocytes and HNP1-3 secretion by neutrophils. Naunyn Schmiedebergs Arch Pharmacol. 
2011;383(5):447-55. 
110. Birch PJ, Grossman CJ, Hayes AG. Kynurenate and FG9041 have both 
competitive and non-competitive antagonist actions at excitatory amino acid receptors. 
European Journal of Pharmacology. 1988;151(2):313-5. 
111. Agudelo LZ, Femenia T, Orhan F, Porsmyr-Palmertz M, Goiny M, Martinez-
Redondo V, et al. Skeletal Muscle PGC-1alpha1 Modulates Kynurenine Metabolism and 
Mediates Resilience to Stress-Induced Depression. Cell. 2014;159(1):33-45. 
112. Agudelo LZ, Ferreira DMS, Cervenka I, Bryzgalova G, Dadvar S, Jannig PR, 
et al. Kynurenic Acid and Gpr35 Regulate Adipose Tissue Energy Homeostasis and 
Inflammation. Cell Metabolism. 2018;27(2):378-92.e5. 
113. Fallarino F, Grohmann U, Vacca C, Bianchi R, Orabona C, Spreca A, et al. T 
cell apoptosis by tryptophan catabolism. Cell Death Differ. 2002;9(10):1069-77. 
114. Favre D, Mold J, Hunt PW, Kanwar B, Loke P, Seu L, et al. Tryptophan 
catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells 
in HIV disease. Sci Transl Med. 2010;2(32):32ra6. 
115. Hayashi T, Mo JH, Gong X, Rossetto C, Jang A, Beck L, et al. 3-
Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by 
inducing T cell apoptosis. Proc Natl Acad Sci U S A. 2007;104(47):18619-24. 
 58 
116. Lee SM, Lee YS, Choi JH, Park SG, Choi IW, Joo YD, et al. Tryptophan 
metabolite 3-hydroxyanthranilic acid selectively induces activated T cell death via 
intracellular GSH depletion. Immunol Lett. 2010;132(1-2):53-60. 
117. Pae HO, Oh GS, Lee BS, Rim JS, Kim YM, Chung HT. 3-Hydroxyanthranilic 
acid, one of L-tryptophan metabolites, inhibits monocyte chemoattractant protein-1 secretion 
and vascular cell adhesion molecule-1 expression via heme oxygenase-1 induction in human 
umbilical vein endothelial cells. Atherosclerosis. 2006;187(2):274-84. 
118. Morita T, Saito K, Takemura M, Maekawa N, Fujigaki S, Fujii H, et al. 3-
Hydroxyanthranilic acid, an L-tryptophan metabolite, induces apoptosis in monocyte-derived 
cells stimulated by interferon-gamma. Ann Clin Biochem. 2001;38(Pt 3):242-51. 
119. Macintyre AN, Gerriets VA, Nichols AG, Michalek RD, Rudolph MC, 
Deoliveira D, et al. The glucose transporter Glut1 is selectively essential for CD4 T cell 
activation and effector function. Cell Metab. 2014;20(1):61-72. 
120. Tannahill GM, Curtis AM, Adamik J, Palsson-McDermott EM, McGettrick 
AF, Goel G, et al. Succinate is an inflammatory signal that induces IL-1beta through HIF-
1alpha. Nature. 2013;496(7444):238-42. 
121. Zhang S, Hulver MW, McMillan RP, Cline MA, Gilbert ER. The pivotal role 
of pyruvate dehydrogenase kinases in metabolic flexibility. Nutr Metab (Lond). 
2014;11(1):10. 
122. Wende AR, Huss JM, Schaeffer PJ, Giguere V, Kelly DP. PGC-1alpha 
coactivates PDK4 gene expression via the orphan nuclear receptor ERRalpha: a mechanism 
for transcriptional control of muscle glucose metabolism. Mol Cell Biol. 2005;25(24):10684-
94. 
123. Connaughton S, Chowdhury F, Attia RR, Song S, Zhang Y, Elam MB, et al. 
Regulation of pyruvate dehydrogenase kinase isoform 4 (PDK4) gene expression by 
glucocorticoids and insulin. Mol Cell Endocrinol. 2010;315(1-2):159-67. 
124. Michelakis ED, Sutendra G, Dromparis P, Webster L, Haromy A, Niven E, et 
al. Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med. 
2010;2(31):31ra4. 
125. Sun RC, Fadia M, Dahlstrom JE, Parish CR, Board PG, Blackburn AC. 
Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell 
growth in vitro and in vivo. Breast Cancer Res Treat. 2010;120(1):253-60. 
126. He W, Miao FJ, Lin DC, Schwandner RT, Wang Z, Gao J, et al. Citric acid 
cycle intermediates as ligands for orphan G-protein-coupled receptors. Nature. 
2004;429(6988):188-93. 
127. Rubic T, Lametschwandtner G, Jost S, Hinteregger S, Kund J, Carballido-
Perrig N, et al. Triggering the succinate receptor GPR91 on dendritic cells enhances 
immunity. Nat Immunol. 2008;9(11):1261-9. 
128. Littlewood-Evans A, Sarret S, Apfel V, Loesle P, Dawson J, Zhang J, et al. 
GPR91 senses extracellular succinate released from inflammatory macrophages and 
exacerbates rheumatoid arthritis. J Exp Med. 2016;213(9):1655-62. 
129. Warburg O, Wind F, Negelein E. Über den Stoffwechsel von Tumoren im 
Körper. Klinische Wochenschrift. 1926;5(19):829-32. 
  59 
130. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg 
effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029-33. 
131. Marelli-Berg FM, Fu H, Mauro C. Molecular mechanisms of metabolic 
reprogramming in proliferating cells: implications for T-cell-mediated immunity. 
Immunology. 2012;136(4):363-9. 
132. Rodriguez-Prados JC, Traves PG, Cuenca J, Rico D, Aragones J, Martin-Sanz 
P, et al. Substrate fate in activated macrophages: a comparison between innate, classic, and 
alternative activation. J Immunol. 2010;185(1):605-14. 
133. Eleftheriadis T, Pissas G, Antoniadi G, Spanoulis A, Liakopoulos V, Stefanidis 
I. Indoleamine 2,3-dioxygenase increases p53 levels in alloreactive human T cells, and both 
indoleamine 2,3-dioxygenase and p53 suppress glucose uptake, glycolysis and proliferation. 
Int Immunol. 2014;26(12):673-84. 
134. Eleftheriadis T, Pissas G, Yiannaki E, Markala D, Arampatzis S, Antoniadi G, 
et al. Inhibition of indoleamine 2,3-dioxygenase in mixed lymphocyte reaction affects 
glucose influx and enzymes involved in aerobic glycolysis and glutaminolysis in alloreactive 
T-cells. Hum Immunol. 2013;74(12):1501-9. 
135. Williams KJ, Tabas I. The response-to-retention hypothesis of early 
atherogenesis. Arterioscler Thromb Vasc Biol. 1995;15(5):551-61. 
136. Boren J, Williams KJ. The central role of arterial retention of cholesterol-rich 
apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of 
simplicity. Curr Opin Lipidol. 2016;27(5):473-83. 
137. Flood C, Gustafsson M, Richardson PE, Harvey SC, Segrest JP, Boren J. 
Identification of the proteoglycan binding site in apolipoprotein B48. J Biol Chem. 
2002;277(35):32228-33. 
138. Tran-Lundmark K, Tran PK, Paulsson-Berne G, Friden V, Soininen R, 
Tryggvason K, et al. Heparan sulfate in perlecan promotes mouse atherosclerosis: roles in 
lipid permeability, lipid retention, and smooth muscle cell proliferation. Circ Res. 
2008;103(1):43-52. 
139. Dai G, Kaazempur-Mofrad MR, Natarajan S, Zhang Y, Vaughn S, Blackman 
BR, et al. Distinct endothelial phenotypes evoked by arterial waveforms derived from 
atherosclerosis-susceptible and -resistant regions of human vasculature. Proc Natl Acad Sci U 
S A. 2004;101(41):14871-6. 
140. Armstrong SM, Sugiyama MG, Fung KY, Gao Y, Wang C, Levy AS, et al. A 
novel assay uncovers an unexpected role for SR-BI in LDL transcytosis. Cardiovasc Res. 
2015;108(2):268-77. 
141. Fernandez-Hernando C, Yu J, Suarez Y, Rahner C, Davalos A, Lasuncion MA, 
et al. Genetic evidence supporting a critical role of endothelial caveolin-1 during the 
progression of atherosclerosis. Cell Metab. 2009;10(1):48-54. 
142. Witztum JL. The oxidation hypothesis of atherosclerosis. The Lancet. 
1994;344(8925):793-5. 
143. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T 
lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. 
Proc Natl Acad Sci U S A. 1995;92(9):3893-7. 
 60 
144. Ketelhuth DF, Rios FJ, Wang Y, Liu H, Johansson ME, Fredrikson GN, et al. 
Identification of a danger-associated peptide from apolipoprotein B100 (ApoBDS-1) that 
triggers innate proatherogenic responses. Circulation. 2011;124(22):2433-43, 1-7. 
145. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, et al. 
Lack of effect of long-term supplementation with beta carotene on the incidence of malignant 
neoplasms and cardiovascular disease. N Engl J Med. 1996;334(18):1145-9. 
146. Hodis HN, Mack WJ, LaBree L, Mahrer PR, Sevanian A, Liu CR, et al. Alpha-
tocopherol supplementation in healthy individuals reduces low-density lipoprotein oxidation 
but not atherosclerosis: the Vitamin E Atherosclerosis Prevention Study (VEAPS). 
Circulation. 2002;106(12):1453-9. 
147. Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. 
Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's 
Health Study: a randomized controlled trial. JAMA. 2005;294(1):56-65. 
148. Cybulsky MI, Gimbrone MA, Jr. Endothelial expression of a mononuclear 
leukocyte adhesion molecule during atherogenesis. Science. 1991;251(4995):788-91. 
149. Libby P, Pasterkamp G. Requiem for the 'vulnerable plaque'. Eur Heart J. 
2015;36(43):2984-7. 
150. Robbins CS, Hilgendorf I, Weber GF, Theurl I, Iwamoto Y, Figueiredo JL, et 
al. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat 
Med. 2013;19(9):1166-72. 
151. Boullier A, Gillotte KL, Horkko S, Green SR, Friedman P, Dennis EA, et al. 
The binding of oxidized low density lipoprotein to mouse CD36 is mediated in part by 
oxidized phospholipids that are associated with both the lipid and protein moieties of the 
lipoprotein. J Biol Chem. 2000;275(13):9163-9. 
152. Kunjathoor VV, Febbraio M, Podrez EA, Moore KJ, Andersson L, Koehn S, et 
al. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the 
uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol 
Chem. 2002;277(51):49982-8. 
153. Gerrity RG. The role of the monocyte in atherogenesis: I. Transition of blood-
borne monocytes into foam cells in fatty lesions. Am J Pathol. 1981;103:181-90. 
154. Moore KJ, Kunjathoor VV, Koehn SL, Manning JJ, Tseng AA, Silver JM, et al. 
Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not 
ameliorate atherosclerosis in hyperlipidemic mice. J Clin Invest. 2005;115(8):2192-201. 
155. Yuasa-Kawase M, Masuda D, Yamashita T, Kawase R, Nakaoka H, Inagaki M, 
et al. Patients with CD36 deficiency are associated with enhanced atherosclerotic 
cardiovascular diseases. J Atheroscler Thromb. 2012;19(3):263-75. 
156. van Eck M, Bos IS, Kaminski WE, Orso E, Rothe G, Twisk J, et al. Leukocyte 
ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues. 
Proc Natl Acad Sci U S A. 2002;99(9):6298-303. 
157. Westerterp M, Murphy AJ, Wang M, Pagler TA, Vengrenyuk Y, Kappus MS, 
et al. Deficiency of ATP-binding cassette transporters A1 and G1 in macrophages increases 
inflammation and accelerates atherosclerosis in mice. Circ Res. 2013;112(11):1456-65. 
  61 
158. van Gils JM, Derby MC, Fernandes LR, Ramkhelawon B, Ray TD, Rayner KJ, 
et al. The neuroimmune guidance cue netrin-1 promotes atherosclerosis by inhibiting the 
emigration of macrophages from plaques. Nat Immunol. 2012;13(2):136-43. 
159. Andres V, Pello OM, Silvestre-Roig C. Macrophage proliferation and apoptosis 
in atherosclerosis. Curr Opin Lipidol. 2012;23(5):429-38. 
160. Karunakaran D, Geoffrion M, Wei L, Gan W, Richards L, Shangari P, et al. 
Targeting macrophage necroptosis for therapeutic and diagnostic interventions in 
atherosclerosis. Sci Adv. 2016;2(7):e1600224. 
161. Grebe A, Hoss F, Latz E. NLRP3 Inflammasome and the IL-1 Pathway in 
Atherosclerosis. Circ Res. 2018;122(12):1722-40. 
162. Thorp E, Subramanian M, Tabas I. The role of macrophages and dendritic cells 
in the clearance of apoptotic cells in advanced atherosclerosis. Eur J Immunol. 
2011;41(9):2515-8. 
163. Sheedy FJ, Grebe A, Rayner KJ, Kalantari P, Ramkhelawon B, Carpenter SB, 
et al. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular 
nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat Immunol. 
2013;14(8):812-20. 
164. Rhoads JP, Lukens JR, Wilhelm AJ, Moore JL, Mendez-Fernandez Y, 
Kanneganti TD, et al. Oxidized Low-Density Lipoprotein Immune Complex Priming of the 
Nlrp3 Inflammasome Involves TLR and FcgammaR Cooperation and Is Dependent on 
CARD9. J Immunol. 2017;198(5):2105-14. 
165. Rajamaki K, Lappalainen J, Oorni K, Valimaki E, Matikainen S, Kovanen PT, 
et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel 
link between cholesterol metabolism and inflammation. PLoS One. 2010;5(7):e11765. 
166. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, et al. 
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. 
Nature. 2010;464(7293):1357-61. 
167. Menu P, Pellegrin M, Aubert JF, Bouzourene K, Tardivel A, Mazzolai L, et al. 
Atherosclerosis in ApoE-deficient mice progresses independently of the NLRP3 
inflammasome. Cell Death Dis. 2011;2:e137. 
168. Paramel Varghese G, Folkersen L, Strawbridge RJ, Halvorsen B, Yndestad A, 
Ranheim T, et al. NLRP3 Inflammasome Expression and Activation in Human 
Atherosclerosis. J Am Heart Assoc. 2016;5(5). 
169. Galea J, Armstrong J, Gadsdon P, Holden H, Francis SE, Holt CM. Interleukin-
1 beta in coronary arteries of patients with ischemic heart disease. Arterioscler Thromb Vasc 
Biol. 1996;16(8):1000-6. 
170. Elhage R, Maret A, Pieraggi MT, Thiers JC, Arnal JF, Bayard F. Differential 
effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-
streak formation in apolipoprotein E-deficient mice. Circulation. 1998;97(3):242-4. 
171. Kirii H, Niwa T, Yamada Y, Wada H, Saito K, Iwakura Y, et al. Lack of 
interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. 
Arterioscler Thromb Vasc Biol. 2003;23(4):656-60. 
 62 
172. Cho KY, Miyoshi H, Kuroda S, Yasuda H, Kamiyama K, Nakagawara J, et al. 
The Phenotype of Infiltrating Macrophages Influences Arteriosclerotic Plaque Vulnerability 
in the Carotid Artery. Journal of Stroke and Cerebrovascular Diseases. 2013;22(7):910-8. 
173. Lee CW, Hwang I, Park CS, Lee H, Park DW, Kang SJ, et al. Macrophage 
heterogeneity of culprit coronary plaques in patients with acute myocardial infarction or 
stable angina. Am J Clin Pathol. 2013;139(3):317-22. 
174. Stoger JL, Gijbels MJ, van der Velden S, Manca M, van der Loos CM, Biessen 
EA, et al. Distribution of macrophage polarization markers in human atherosclerosis. 
Atherosclerosis. 2012;225(2):461-8. 
175. Kadl A, Meher AK, Sharma PR, Lee MY, Doran AC, Johnstone SR, et al. 
Identification of a novel macrophage phenotype that develops in response to atherogenic 
phospholipids via Nrf2. Circ Res. 2010;107(6):737-46. 
176. Singhal A, Subramanian M. Colony stimulating factors (CSFs): Complex roles 
in atherosclerosis. Cytokine. 2019;122:154190. 
177. Di Gregoli K, Johnson JL. Role of colony-stimulating factors in atherosclerosis. 
Curr Opin Lipidol. 2012;23(5):412-21. 
178. da Silva RF, Lappalainen J, Lee-Rueckert M, Kovanen PT. Conversion of 
human M-CSF macrophages into foam cells reduces their proinflammatory responses to 
classical M1-polarizing activation. Atherosclerosis. 2016;248:170-8. 
179. Bobryshev Y, Lord RS. Mapping of vascular dendritic cells in atherosclerotic 
arteries suggests their involvement in local immune-inflammatory reactions. Cardiovascular 
Research. 1998;37(3):799-810. 
180. Gautier EL, Huby T, Saint-Charles F, Ouzilleau B, Pirault J, Deswaerte V, et al. 
Conventional dendritic cells at the crossroads between immunity and cholesterol homeostasis 
in atherosclerosis. Circulation. 2009;119(17):2367-75. 
181. Buono C, Pang H, Uchida Y, Libby P, Sharpe AH, Lichtman AH. B7-1/B7-2 
costimulation regulates plaque antigen-specific T-cell responses and atherogenesis in low-
density lipoprotein receptor-deficient mice. Circulation. 2004;109(16):2009-15. 
182. Subramanian M, Thorp E, Hansson GK, Tabas I. Treg-mediated suppression of 
atherosclerosis requires MYD88 signaling in DCs. J Clin Invest. 2013;123(1):179-88. 
183. Forteza MJ, Polyzos KA, Baumgartner R, Suur BE, Mussbacher M, Johansson 
DK, et al. Activation of the Regulatory T-Cell/Indoleamine 2,3-Dioxygenase Axis Reduces 
Vascular Inflammation and Atherosclerosis in Hyperlipidemic Mice. Front Immunol. 
2018;9:950. 
184. Ovchinnikova OA, Folkersen L, Persson J, Lindeman JH, Ueland T, Aukrust P, 
et al. The collagen cross-linking enzyme lysyl oxidase is associated with the healing of 
human atherosclerotic lesions. J Intern Med. 2014;276(5):525-36. 
185. Feil S, Fehrenbacher B, Lukowski R, Essmann F, Schulze-Osthoff K, Schaller 
M, et al. Transdifferentiation of vascular smooth muscle cells to macrophage-like cells during 
atherogenesis. Circ Res. 2014;115(7):662-7. 
186. Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK. Regional 
accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic 
plaque. Arteriosclerosis. 1986;6(2):131-8. 
  63 
187. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture 
or erosion of thrombosed coronary atherosclerotic plaques is characterized by an 
inflammatory process irrespective of the dominant plaque morphology. Circulation. 
1994;89(1):36-44. 
188. Zhou X, Nicoletti A, Elhage R, Hansson GK. Transfer of CD4(+) T cells 
aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation. 
2000;102(24):2919-22. 
189. Huber SA, Sakkinen P, David C, Newell MK, Tracy RP. T helper-cell 
phenotype regulates atherosclerosis in mice under conditions of mild hypercholesterolemia. 
Circulation. 2001;103(21):2610-6. 
190. Hermansson A, Ketelhuth DF, Strodthoff D, Wurm M, Hansson EM, Nicoletti 
A, et al. Inhibition of T cell response to native low-density lipoprotein reduces 
atherosclerosis. J Exp Med. 2010;207(5):1081-93. 
191. Ruuth M, Nguyen SD, Vihervaara T, Hilvo M, Laajala TD, Kondadi PK, et al. 
Susceptibility of low-density lipoprotein particles to aggregate depends on particle lipidome, 
is modifiable, and associates with future cardiovascular deaths. Eur Heart J. 
2018;39(27):2562-73. 
192. Gupta S, Pablo AM, Jiang X, Wang N, Tall AR, Schindler C. IFN-gamma 
potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest. 1997;99(11):2752-61. 
193. Buono C, Come CE, Stavrakis G, Maguire GF, Connelly PW, Lichtman AH. 
Influence of interferon-gamma on the extent and phenotype of diet-induced atherosclerosis in 
the LDLR-deficient mouse. Arterioscler Thromb Vasc Biol. 2003;23(3):454-60. 
194. Buono C, Binder CJ, Stavrakis G, Witztum JL, Glimcher LH, Lichtman AH. T-
bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. 
Proc Natl Acad Sci U S A. 2005;102(5):1596-601. 
195. Agrawal S, Febbraio M, Podrez E, Cathcart MK, Stark GR, Chisolm GM. 
Signal transducer and activator of transcription 1 is required for optimal foam cell formation 
and atherosclerotic lesion development. Circulation. 2007;115(23):2939-47. 
196. Frostegård J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U, et 
al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-
inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis. 1999;145(1):33-
43. 
197. King VL, Szilvassy SJ, Daugherty A. Interleukin-4 deficiency decreases 
atherosclerotic lesion formation in a site-specific manner in female LDL receptor-/- mice. 
Arterioscler Thromb Vasc Biol. 2002;22(3):456-61. 
198. Binder CJ, Hartvigsen K, Chang MK, Miller M, Broide D, Palinski W, et al. 
IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects 
from atherosclerosis. J Clin Invest. 2004;114(3):427-37. 
199. Cardilo-Reis L, Gruber S, Schreier SM, Drechsler M, Papac-Milicevic N, 
Weber C, et al. Interleukin-13 protects from atherosclerosis and modulates plaque 
composition by skewing the macrophage phenotype. EMBO Mol Med. 2012;4(10):1072-86. 
200. Smith E, Prasad KM, Butcher M, Dobrian A, Kolls JK, Ley K, et al. Blockade 
of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. 
Circulation. 2010;121(15):1746-55. 
 64 
201. Gistera A, Robertson AK, Andersson J, Ketelhuth DF, Ovchinnikova O, 
Nilsson SK, et al. Transforming growth factor-beta signaling in T cells promotes stabilization 
of atherosclerotic plaques through an interleukin-17-dependent pathway. Sci Transl Med. 
2013;5(196):196ra00. 
202. Maganto-Garcia E, Tarrio ML, Grabie N, Bu DX, Lichtman AH. Dynamic 
changes in regulatory T cells are linked to levels of diet-induced hypercholesterolemia. 
Circulation. 2011;124(2):185-95. 
203. Klingenberg R, Gerdes N, Badeau RM, Gistera A, Strodthoff D, Ketelhuth DF, 
et al. Depletion of FOXP3+ regulatory T cells promotes hypercholesterolemia and 
atherosclerosis. J Clin Invest. 2013;123(3):1323-34. 
204. Caligiuri G, Rudling M, Ollivier V, Jacob MP, Michel JB, Hansson GK, et al. 
Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins 
in apolipoprotein E knockout mice. Mol Med. 2003;9(1-2):10-7. 
205. Robertson AK, Rudling M, Zhou X, Gorelik L, Flavell RA, Hansson GK. 
Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. J Clin Invest. 
2003;112(9):1342-50. 
206. Mor A, Luboshits G, Planer D, Keren G, George J. Altered status of 
CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes. Eur Heart J. 
2006;27(21):2530-7. 
207. Wigren M, Bjorkbacka H, Andersson L, Ljungcrantz I, Fredrikson GN, Persson 
M, et al. Low levels of circulating CD4+FoxP3+ T cells are associated with an increased risk 
for development of myocardial infarction but not for stroke. Arterioscler Thromb Vasc Biol. 
2012;32(8):2000-4. 
208. Houtkamp MA, de Boer OJ, van der Loos CM, van der Wal AC, Becker AE. 
Adventitial infiltrates associated with advanced atherosclerotic plaques: structural 
organization suggests generation of local humoral immune responses. The Journal of 
Pathology. 2001;193(2):263-9. 
209. Caligiuri G, Nicoletti A, Poirier B, Hansson GK. Protective immunity against 
atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest. 
2002;109(6):745-53. 
210. Ait-Oufella H, Herbin O, Bouaziz JD, Binder CJ, Uyttenhove C, Laurans L, et 
al. B cell depletion reduces the development of atherosclerosis in mice. J Exp Med. 
2010;207(8):1579-87. 
211. Strom AC, Cross AJ, Cole JE, Blair PA, Leib C, Goddard ME, et al. B 
regulatory cells are increased in hypercholesterolaemic mice and protect from lesion 
development via IL-10. Thromb Haemost. 2015;114(4):835-47. 
212. Yla-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, Witztum JL. 
Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized 
LDL. Arterioscler Thromb. 1994;14(1):32-40. 
213. Lewis MJ, Malik TH, Ehrenstein MR, Boyle JJ, Botto M, Haskard DO. 
Immunoglobulin M is required for protection against atherosclerosis in low-density 
lipoprotein receptor-deficient mice. Circulation. 2009;120(5):417-26. 
214. Kyaw T, Tay C, Khan A, Dumouchel V, Cao A, To K, et al. Conventional B2 
B cell depletion ameliorates whereas its adoptive transfer aggravates atherosclerosis. J 
Immunol. 2010;185(7):4410-9. 
  65 
215. Centa M, Jin H, Hofste L, Hellberg S, Busch A, Baumgartner R, et al. Germinal 
Center-Derived Antibodies Promote Atherosclerosis Plaque Size and Stability. Circulation. 
2019;139(21):2466-82. 
216. Pertovaara M, Raitala A, Juonala M, Lehtimaki T, Huhtala H, Oja SS, et al. 
Indoleamine 2,3-dioxygenase enzyme activity correlates with risk factors for atherosclerosis: 
the Cardiovascular Risk in Young Finns Study. Clin Exp Immunol. 2007;148(1):106-11. 
217. Munipally PK, Agraharm SG, Valavala VK, Gundae S, Turlapati NR. 
Evaluation of indoleamine 2,3-dioxygenase expression and kynurenine pathway metabolites 
levels in serum samples of diabetic retinopathy patients. Arch Physiol Biochem. 
2011;117(5):254-8. 
218. Oxenkrug GF, Turski WA, Zgrajka W, Weinstock JV, Summergrad P. 
Tryptophan-kynurenine metabolism and insulin resistance in hepatitis C patients. Hepat Res 
Treat. 2013;2013:149247. 
219. Kotake Y, Ueda T, Mori T, Igaki S, Hattori M. Abnormal tryptophan 
metabolism and experimental diabetes by xanthurenic acid (XA). Acta Vitaminol Enzymol. 
1975;29(1-6):236-9. 
220. Hattori M, Kotake Y, Kotake Y. Studies on the urinary excretion of xanthurenic 
acid in diabetics. Acta Vitaminol Enzymol. 1984;6(3):221-8. 
221. Okamoto H. Regulation of proinsulin synthesis in pancreatic islets and a new 
aspect to insulin-dependent diabetes. Mol Cell Biochem. 1981;37(1):43-61. 
222. Fallarino F, Volpi C, Zelante T, Vacca C, Calvitti M, Fioretti MC, et al. IDO 
mediates TLR9-driven protection from experimental autoimmune diabetes. J Immunol. 
2009;183(10):6303-12. 
223. Sarkar SA, Wong R, Hackl SI, Moua O, Gill RG, Wiseman A, et al. Induction 
of indoleamine 2,3-dioxygenase by interferon-gamma in human islets. Diabetes. 
2007;56(1):72-9. 
224. Wang Y, Liu H, McKenzie G, Witting PK, Stasch JP, Hahn M, et al. 
Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat 
Med. 2010;16(3):279-85. 
225. Changsirivathanathamrong D, Wang Y, Rajbhandari D, Maghzal GJ, Mak 
WM, Woolfe C, et al. Tryptophan metabolism to kynurenine is a potential novel contributor 
to hypotension in human sepsis. Crit Care Med. 2011;39(12):2678-83. 
226. Jung ID, Lee MG, Chang JH, Lee JS, Jeong YI, Lee CM, et al. Blockade of 
indoleamine 2,3-dioxygenase protects mice against lipopolysaccharide-induced endotoxin 
shock. J Immunol. 2009;182(5):3146-54. 
227. Padberg JS, Van Meurs M, Kielstein JT, Martens-Lobenhoffer J, Bode-Boger 
SM, Zijlstra JG, et al. Indoleamine-2,3-dioxygenase activity in experimental human 
endotoxemia. Exp Transl Stroke Med. 2012;4(1):24. 
228. Ito S, Komatsu K, Tsukamoto K, Sved AF. Excitatory amino acids in the rostral 
ventrolateral medulla support blood pressure in spontaneously hypertensive rats. 
Hypertension. 2000;35(1 Pt 2):413-7. 
229. Kwok JB, Kapoor R, Gotoda T, Iwamoto Y, Iizuka Y, Yamada N, et al. A 
missense mutation in kynurenine aminotransferase-1 in spontaneously hypertensive rats. J 
Biol Chem. 2002;277(39):35779-82. 
 66 
230. Chang MY, Smith C, DuHadaway JB, Pyle JR, Boulden J, Soler AP, et al. 
Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory 
enzyme indoleamine 2,3-dioxygenase. Cancer Biol Ther. 2011;12(12):1050-8. 
231. Zhang L, Ovchinnikova O, Jonsson A, Lundberg AM, Berg M, Hansson GK, et 
al. The tryptophan metabolite 3-hydroxyanthranilic acid lowers plasma lipids and decreases 
atherosclerosis in hypercholesterolaemic mice. Eur Heart J. 2012;33(16):2025-34. 
232. Wirleitner B, Rudzite V, Neurauter G, Murr C, Kalnins U, Erglis A, et al. 
Immune activation and degradation of tryptophan in coronary heart disease. Eur J Clin Invest. 
2003;33(7):550-4. 
233. Pedersen ER, Midttun O, Ueland PM, Schartum-Hansen H, Seifert R, Igland J, 
et al. Systemic markers of interferon-gamma-mediated immune activation and long-term 
prognosis in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol. 
2011;31(3):698-704. 
234. Pedersen ER, Tuseth N, Eussen SJ, Ueland PM, Strand E, Svingen GF, et al. 
Associations of plasma kynurenines with risk of acute myocardial infarction in patients with 
stable angina pectoris. Arterioscler Thromb Vasc Biol. 2015;35(2):455-62. 
235. Pedersen ER, Svingen GF, Schartum-Hansen H, Ueland PM, Ebbing M, 
Nordrehaug JE, et al. Urinary excretion of kynurenine and tryptophan, cardiovascular events, 
and mortality after elective coronary angiography. Eur Heart J. 2013;34(34):2689-96. 
236. Sulo G, Vollset SE, Nygard O, Midttun O, Ueland PM, Eussen SJ, et al. 
Neopterin and kynurenine-tryptophan ratio as predictors of coronary events in older adults, 
the Hordaland Health Study. Int J Cardiol. 2013;168(2):1435-40. 
237. Eussen SJ, Ueland PM, Vollset SE, Nygard O, Midttun O, Sulo G, et al. 
Kynurenines as predictors of acute coronary events in the Hordaland Health Study. Int J 
Cardiol. 2015;189:18-24. 
238. Metghalchi S, Ponnuswamy P, Simon T, Haddad Y, Laurans L, Clement M, et 
al. Indoleamine 2,3-Dioxygenase Fine-Tunes Immune Homeostasis in Atherosclerosis and 
Colitis through Repression of Interleukin-10 Production. Cell Metab. 2015;22(3):460-71. 
239. Holmes DR, Jr., Savage M, LaBlanche JM, Grip L, Serruys PW, Fitzgerald P, 
et al. Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. 
Circulation. 2002;106(10):1243-50. 
240. Brouns R, Verkerk R, Aerts T, De Surgeloose D, Wauters A, Scharpe S, et al. 
The role of tryptophan catabolism along the kynurenine pathway in acute ischemic stroke. 
Neurochem Res. 2010;35(9):1315-22. 
241. Li M, Kwok MK, Fong SSM, Schooling CM. Indoleamine 2,3-dioxygenase 
and ischemic heart disease: a Mendelian Randomization study. Sci Rep. 2019;9(1):8491. 
242. Cole JE, Astola N, Cribbs AP, Goddard ME, Park I, Green P, et al. Indoleamine 
2,3-dioxygenase-1 is protective in atherosclerosis and its metabolites provide new 
opportunities for drug development. Proc Natl Acad Sci U S A. 2015;112(42):13033-8. 
243. Daissormont IT, Christ A, Temmerman L, Sampedro Millares S, Seijkens T, 
Manca M, et al. Plasmacytoid dendritic cells protect against atherosclerosis by tuning T-cell 
proliferation and activity. Circ Res. 2011;109(12):1387-95. 
  67 
244. Yun TJ, Lee JS, Machmach K, Shim D, Choi J, Wi YJ, et al. Indoleamine 2,3-
Dioxygenase-Expressing Aortic Plasmacytoid Dendritic Cells Protect against Atherosclerosis 
by Induction of Regulatory T Cells. Cell Metab. 2016;23(5):852-66. 
245. Laurans L, Venteclef N, Haddad Y, Chajadine M, Alzaid F, Metghalchi S, et al. 
Genetic deficiency of indoleamine 2,3-dioxygenase promotes gut microbiota-mediated 
metabolic health. Nat Med. 2018;24(8):1113-20. 
246. Cuffy MC, Silverio AM, Qin L, Wang Y, Eid R, Brandacher G, et al. Induction 
of Indoleamine 2,3-Dioxygenase in Vascular Smooth Muscle Cells by 
Interferon-  Contributes to Medial Immunoprivilege. The Journal of Immunology. 
2007;179(8):5246-54. 
247. Emami H, Singh P, MacNabb M, Vucic E, Lavender Z, Rudd JH, et al. Splenic 
metabolic activity predicts risk of future cardiovascular events: demonstration of a 
cardiosplenic axis in humans. JACC Cardiovasc Imaging. 2015;8(2):121-30. 
248. Marnane M, Merwick A, Sheehan OC, Hannon N, Foran P, Grant T, et al. 
Carotid plaque inflammation on 18F-fluorodeoxyglucose positron emission tomography 
predicts early stroke recurrence. Ann Neurol. 2012;71(5):709-18. 
249. Figueroa AL, Abdelbaky A, Truong QA, Corsini E, MacNabb MH, Lavender 
ZR, et al. Measurement of arterial activity on routine FDG PET/CT images improves 
prediction of risk of future CV events. JACC Cardiovasc Imaging. 2013;6(12):1250-9. 
250. Tomas L, Edsfeldt A, Mollet IG, Perisic Matic L, Prehn C, Adamski J, et al. 
Altered metabolism distinguishes high-risk from stable carotid atherosclerotic plaques. Eur 
Heart J. 2018;39(24):2301-10. 
251. Sarrazy V, Viaud M, Westerterp M, Ivanov S, Giorgetti-Peraldi S, Guinamard 
R, et al. Disruption of Glut1 in Hematopoietic Stem Cells Prevents Myelopoiesis and 
Enhanced Glucose Flux in Atheromatous Plaques of ApoE(-/-) Mice. Circ Res. 
2016;118(7):1062-77. 
252. Christ A, Gunther P, Lauterbach MAR, Duewell P, Biswas D, Pelka K, et al. 
Western Diet Triggers NLRP3-Dependent Innate Immune Reprogramming. Cell. 
2018;172(1-2):162-75 e14. 
253. Reboldi A, Dang EV, McDonald JG, Liang G, Russell DW, Cyster JG. 25-
Hydroxycholesterol suppresses interleukin 1 driven inflammation downstream of type I 
interferon. Science. 2014;345(6197). 
254. Xiao H, Lu M, Lin TY, Chen Z, Chen G, Wang WC, et al. Sterol regulatory 
element binding protein 2 activation of NLRP3 inflammasome in endothelium mediates 
hemodynamic-induced atherosclerosis susceptibility. Circulation. 2013;128(6):632-42. 
255. Li Y, Xu S, Jiang B, Cohen RA, Zang M. Activation of sterol regulatory 
element binding protein and NLRP3 inflammasome in atherosclerotic lesion development in 
diabetic pigs. PLoS One. 2013;8(6):e67532. 
256. Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM, Maeda N. Generation of 
mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic 
stem cells. Proc Natl Acad Sci U S A. 1992;89(10):4471-5. 
257. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J. 
Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by 
adenovirus-mediated gene delivery. J Clin Invest. 1993;92(2):883-93. 
 68 
258. Rothwell PM, Pendlebury ST, Wardlaw J, Warlow CP. Critical appraisal of the 
design and reporting of studies of imaging and measurement of carotid stenosis. Stroke. 
2000;31(6):1444-50. 
259. O'Brien KD, Allen MD, McDonald TO, Chait A, Harlan JM, Fishbein D, et al. 
Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques. 
Implications for the mode of progression of advanced coronary atherosclerosis. J Clin Invest. 
1993;92(2):945-51. 
260. Braun M. Cellular adhesion molecules on vascular smooth muscle cells. 
Cardiovascular Research. 1999;41(2):395-401. 
261. Cai Q, Lanting L, Natarajan R. Growth factors induce monocyte binding to 
vascular smooth muscle cells: implications for monocyte retention in atherosclerosis. Am J 
Physiol Cell Physiol. 2004;287(3):C707-14. 
262. Lob S, Konigsrainer A, Schafer R, Rammensee HG, Opelz G, Terness P. Levo- 
but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. 
Blood. 2008;111(4):2152-4. 
263. Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, 
Prendergast GC. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target 
of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. 
Cancer Res. 2007;67(15):7082-7. 
264. Qian F, Liao J, Villella J, Edwards R, Kalinski P, Lele S, et al. Effects of 1-
methyltryptophan stereoisomers on IDO2 enzyme activity and IDO2-mediated arrest of 
human T cell proliferation. Cancer Immunol Immunother. 2012;61(11):2013-20. 
265. Agaugue S, Perrin-Cocon L, Coutant F, Andre P, Lotteau V. 1-Methyl-
tryptophan can interfere with TLR signaling in dendritic cells independently of IDO activity. 
J Immunol. 2006;177(4):2061-71. 
266. Schonewille M, de Boer JF, Mele L, Wolters H, Bloks VW, Wolters JC, et al. 
Statins increase hepatic cholesterol synthesis and stimulate fecal cholesterol elimination in 
mice. J Lipid Res. 2016;57(8):1455-64. 
267. Tang JJ, Li JG, Qi W, Qiu WW, Li PS, Li BL, et al. Inhibition of SREBP by a 
small molecule, betulin, improves hyperlipidemia and insulin resistance and reduces 
atherosclerotic plaques. Cell Metab. 2011;13(1):44-56. 
268. Porstmann T, Santos CR, Griffiths B, Cully M, Wu M, Leevers S, et al. SREBP 
activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab. 
2008;8(3):224-36. 
269. Li X, Zhang X, Pan Y, Shi G, Ren J, Fan H, et al. mTOR regulates NLRP3 
inflammasome activation via reactive oxygen species in murine lupus. Acta Biochim Biophys 
Sin (Shanghai). 2018;50(9):888-96. 
270. Fornstedt-Wallin B LJ, Fredriksson G, Schwarcz R, Luthman J. 3-
Hydroxyanthranilic acid accumulation following administration of the 3-hydroxyanthranilic 
acid 3,4-dioxygenase inhibitor NCR-631. Eur J Pharmacol. 1999;10;386(1):15-24. 
271. Niinisalo P, Oksala N, Levula M, Pelto-Huikko M, Jarvinen O, Salenius JP, et 
al. Activation of indoleamine 2,3-dioxygenase-induced tryptophan degradation in advanced 
atherosclerotic plaques: Tampere vascular study. Ann Med. 2010;42(1):55-63. 
  69 
272. Reynolds LM, Ding J, Taylor JR, Lohman K, Soranzo N, de la Fuente A, et al. 
Transcriptomic profiles of aging in purified human immune cells. BMC Genomics. 
2015;16:333. 
273. Lakoski SG, Greenland P, Wong ND, Schreiner PJ, Herrington DM, Kronmal 
RA, et al. Coronary artery calcium scores and risk for cardiovascular events in women 
classified as "low risk" based on Framingham risk score: the multi-ethnic study of 
atherosclerosis (MESA). Arch Intern Med. 2007;167(22):2437-42. 
274. Min BK, Oh CJ, Park S, Lee JM, Go Y, Park BY, et al. Therapeutic effect of 
dichloroacetate against atherosclerosis via hepatic FGF21 induction mediated by acute 
AMPK activation. Exp Mol Med. 2019;51(10):1-12. 
275. Stacpoole PW, Wright EC, Baumgartner TG, Bersin RM, Buchalter S, Curry 
SH, et al. A controlled clinical trial of dichloroacetate for treatment of lactic acidosis in 
adults. The Dichloroacetate-Lactic Acidosis Study Group. N Engl J Med. 
1992;327(22):1564-9. 
276. McCall CE, Zabalawi M, Liu T, Martin A, Long DL, Buechler NL, et al. 
Pyruvate dehydrogenase complex stimulation promotes immunometabolic homeostasis and 
sepsis survival. JCI Insight. 2018;3(15). 
 
